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Under normal conditions, a natural rewarding experience causes depolarization of midbrain
dopaminergic neurons and exocytotic dopamine (DA) release into the synaptic cleft. A tonic
increase of dopamine (DA) in the nucleus accumbens is required for associating everyday events
and behaviors with rewards. The increase in synaptic DA activates presynaptic and postsynaptic
dopamine receptors and results in reward-directed associative learning behaviors. The dopamine
transporter (DAT) clears DA from the synaptic cleft by transporting it back into the presynaptic
terminal, thus terminating DA signal transduction. However, many addictive exogenous
compounds such as amphetamine (AMPH) and cocaine (COC) directly interact with DAT and
produce a much greater phasic augmentation of synaptic DA levels. The dysregulation of
dopaminergic homeostasis has been established as the primary source of numerous neurological
disorders including Parkinson’s disease and drug addiction. DAT’s activity is also associated with
ionic current that can be measured by voltage clamp techniques. Psychostimulants like AMPH and

COC directly interact with DAT altering its ionic currents. The classical view of psychostimulant
action suggests that these drugs can be discriminated based on their effects on DAT activity.
Reuptake inhibitors like COC decrease constitutive leak currents through DAT and prevent DA
transport and thus raise its synaptic concentration. Substrates like AMPH enter the presynaptic
terminal via DAT and thus compete with DA uptake. Under voltage clamp conditions, the transport
of substrate alongside Na+ and other ions give rise to a net inward depolarizing current. The
resulting increase of extracellular DA levels is thus due to competition for transport, reverse
transport, and exocytotic DA release due to DAT-induced depolarization.
Focusing our attention on electrophysiological techniques, we show that certain functional
substrate-type psychostimulants (STPs), but not COC or DA itself, can produce a novel type of
DAT-associated persistent current (IPC) in addition to an initial peak current (ISTP). The persistent
current is distinct from the transport-associated current elicited by DA (IDA) and the constitutive
leak current (IL) through DAT. Unlike IDA and IL, the newly-identified STP-dependent persistent
current, IPC, lasts for many minutes after external substrate removal in the oocyte expression
system. In transiently transfected HEK 293 cells we also see a persistent current that is described
kinetically. HEK 293 cells have faster on and off kinetics (τ1/2) than their counterparts in oocytes
for both DA and S-AMPH induced currents; however, the persistence ratio of S-AMPH to DA
induced off kinetics was comparable in both oocyte and mammalian expression systems. Finally,
we demonstrate drug-induced DAT currents can activate voltage-gated calcium channels (CaV)
associated with dopaminergic excitability mammalian expression system. The electrical coupling
between hDAT and CaV was further investigated in a human midbrain dopaminergic cell line.
Understanding how STPs interact with DAT to produce novel conductance states may facilitate
the development of unique therapeutic strategies to treat psychostimulant abuse.

Chapter 1 BACKGROUND

1.1. Introduction of DAT

The neurotransmitter DA regulates cognition, voluntary movement, motivation, and
reward [7, 9]. As illustrated in Figure 1, DA is synthesized in the cell bodies of dopaminergic
neurons located in the substantia nigra (SN) and the ventral tegmental area (VTA) of the brain.
Upon depolarization of the presynaptic terminal, voltage-gated calcium channels (CaVs) activate
and allow calcium (Ca2+) to enter and to interact with proteins required for vesicular fusion and
exocytotic DA release. DA signaling is a balance of neurotransmitter release during tonic and
phasic activity of dopaminergic neurons and its clearance from the cleft. The primary mechanism
of clearance is reuptake through the dopamine transporter (DAT, SLC6A), and to a lesser extend
degradation by enzymes and diffusion away from the synapse [9]. The plasma membrane protein
DAT regulates DA signal transduction and homeostasis by transporting the released synaptic
neurotransmitter into the presynaptic neuron using Na+ and Cl- electrochemical gradients [10, 11].
Within dopaminergic neurons in the central nervous system (CNS) another transporter, the
vesicular monoamine transporter 2 (VMAT2), uses a proton gradient to recycle and concentrate
cytosolic DA back in synaptic vesicles for subsequent release [12]. DATs are strategically located
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in the soma, dendrites, and perisynaptic areas of dopaminergic neurons [13]. Their proper function
and location are crucial for dopaminergic signaling.

VMAT
2

Figure 1: Dopaminergic synapse DAT is located at the perisynaptic area of dopaminergic
terminal. It transports released synaptic DA back in the presynaptic cell to be repackaged in
vesicles for subsequent release. AMPH and COC interact directly with DAT. AMPH acts as
substrate and is transported, while COC binds the transporter and arrests its function. Figure
adapted from [7].
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Dysfunction in transporter activity or expression levels that affect DA concentration in
different locations of the brain may lead to neurological, psychiatric, and neuroendocrine
disorders. Figure 2 lists some of the disorders associated with either increased or decreased DA
levels in the different dopaminergic pathways [8]. For example, augmentation of DA in the
prefrontal cortex (PFC) is linked to attention deficit hyperactivity disorder (ADHD) and
schizophrenia, while decreased DA levels in the striatum are associated with Parkinson’s and
Huntington’s disease. Increased levels of DA in the nucleus accumbens (NAcc) has been
implicated in drug addiction. Albeit through different mechanisms, all classes of abused drugs
increase extracellular levels of DA particularly in NAcc [14]. The released DA activate DA
receptors which signal higher brain regions, e.g., the prefrontal cortex, to translate motivational
input into behavioral output [15]. The importance of DAT in the psychostimulant dependence is
confirmed in animals with disrupted mesolimbic dopaminergic system (via knock-outs or lesions)
or dopamine receptor antagonists, where abuse related effects of psychostimulants can be
eliminated [16-18]. Moreover, in DAT knock-in mice enhanced psychostimulant reinforcement is
observed [19, 20].

3

Figure 2: Dopaminergic pathways and their involvement in diseased states There are four
major dopaminergic pathways that are involved in numerous neurological psychiatric, and
neuroendocrine diseased. The mesocortical pathway (blue) originates from the ventral
tegmental area (VTA) and projects to the prefrontal cortex (PFC). The mesolimbic pathway
(blue) connects VTA to the nucleus accumbens (nAcb). The nigrostriatal pathway (red) projects
from the substantia nigra to the striatum. Lastly, the tuberoinfundibular pathway (orange)
connects the hypothalamus to the pituitary gland. Disorders associated with each pathway are
listed in the text boxes linked to them. Figure adapted from [8].
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1.2. DAT function
DAT is the primary mediator of synaptic DA clearance. The transport process is Na+ and
Cl- dependent and it is driven by Na+ electrochemical gradient. Transporter function is classically
described as following the alternating access model (AAM) originally defined in 1966 by
Jardetzky for ATPase pumps and since adopted for co-transporters [21]. Flux studies revealed
Michaelis-Menten type relationship between transport and concentration of DA, Na+, and Cl- [10].
Independent studies from Krueger and Schenk’s laboratory found Na+ concentration dependence
on uptake was sigmoidal while Cl- concentration dependence was rectangular hyperbola, hence
assigning a transport stoichiometry of 1DA: 2Na+: 1Cl- per transport cycle [10, 21, 22]. Using
radiolabeled ligand uptake and irreversible binding assays, transporter turnover rate was calculated
to be one full cycle every two seconds; therefore, using the proposed stoichiometry and because
DA is a monovalent cation at physiological pH, one positive charge enters the cell every second
through DAT [10]. Thus, the transporter is predicted to be electrogenic and the current generated
by 1 million transporters acting simultaneously would be 0.16 pA. Nevertheless, numerous reports
exist of the dopamine transporter eliciting much larger currents, well beyond the prediction of
AAM [1, 6, 21, 23]. In addition, Sonders et. al. report a variable number of charges moving though
DAT at different membrane potentials, thus contradicting the fixed stoichiometry model and
proposing transport-uncoupled DAT current [23]. The unaccounted for DAT currents in addition
to the fast reuptake of DA required at the synapse suggest for an alternative and/or combined ion
channel/transporter mechanism of action. Figure 3 depicts a DAT model that has both alternating
access mode (outward open, occluded, inward facing) and ion channel mode of transport [4]. DATgenerated currents through the ion channel mode are sufficient to affect membrane potential and
excitability [24, 25]. Because a number of psychostimulants interact with DAT to produce or alter
5

its ionic currents [1, 2, 6, 26]. The mechanisms by which STPs control DAT activity and modulate
membrane potential is of particular interest.
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Figure 3: Alternating access and channel modes of transport Substrate, Na+, and Cl- bind to
outward facing transporter (i) outer gate closing (black bars) brings DAT to occluded state (ii)
which then transitions to the inward facing conformation (iii) releasing substrate and ions to
cytosol. The empty transporter then returns to the outward facing conformation (i). The
transporter may undergo another transition (dashed lines) to a channel state (iv) where both
gates are open simultaneously and currents are observed following rush of ions down their
electrochemical gradients. Figure adapted from [4].
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1.3. DAT regulation

DAT activity is contingent upon its presence at the cell membrane. DAT is synthesized in
the endoplasmic reticulum (ER), transported to the Golgi for N-glycosylation at the 2nd
extracellular loop and trafficked to the plasma membrane [27]. Different signaling pathways have
shown effect on transporter cell surface expression both constitutively and upon stimulation [28,
29]. DAT has several consensus sites for posttranslational modifications at its cytosolic amino (N)
and carboxyl (C) terminus. On the N terminus a cluster of serine residues are involved in PKC
phosphorylation, which is important in DA efflux. Deletions and mutations of these residues on
DAT results in reduced phosphorylation and internalization of the protein upon PKC activation
[30, 31]. There is evidence for Ca2+/Calmodulin-dependent protein kinase II interactions with the
C-terminus of DAT that regulate DA efflux [32, 33]. Residues 587-596 in DAT’s carboxyl
terminus play a role in its constitutive protein internalization [34]. More recent studies show that
DAT is regulated by PIP2 suggesting the importance of membrane lipid composition in transporter
function [35]. DAT substrates like AMPH and METH cause DAT down-regulation, while DAT
reuptake

inhibitors

or

blockers

cause

transporter

up-regulation

as

immunofluorescence confocal microscopy in mammalian expression system

determined

by

[36, 37]. The

reduction and rise of DAT at the plasma membrane can be further monitored using voltage clamp
techniques where current amplitude and kinetics can be measured for functional transporters [2,
38]. Moreover, DAT regulation by psychostimulants was confirmed by postmortem binding
studies in cocaine overdose victims, showing higher number DAT binding sites [39, 40]. The
numerous DAT regulation mechanisms contribute to an already complex picture of DAT function
and are an active area of research aiming at understanding drug dependence.
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1.4. DAT-associated currents
DAT uses Na+ and Cl- electrochemical gradients for the uphill DA transport. At
physiological pH, DA carries one positive charge (the –NH group has a pKa ~ 10,
www.drugbank.ca). Using voltage clamp techniques one can monitor the ionic currents generated
by the charged species moving through DAT. Various studies show DAT has an inherent leak
current (IL) [1, 2, 6] that is present in the absence of substrates. This current, IL, is observed upon
insertion of the protein in the cell membrane. IL is composed of monovalent cations and is revealed
upon application of DAT inhibitors [23]. Figure 4 shows DA and other substrate, like AMPH,
induce relatively large inward drug-induced currents (IDA and ISTP) representing a net positive
charge entering the cell at potentials near rest. All DAT currents (IL, IDA, and ISTP) can be identified
using DAT reuptake inhibitors like cocaine (COC). COC’s block of inward IL or IDA appears as an
outward deflection of the current trace under voltage clamp conditions, demonstrating the
inhibition of the inward constitutive leak through the transporter [1, 6, 23]. Recently, we described
a new long lasting conduction state of DAT. Following S-AMPH exposure and subsequent
removal, DAT continues to elicit an inward current that persists for many minutes in Xenopus
oocyte expression system. We termed this depolarizing current induced by previous exposure to
S-AMPH the persistent current (IPC) [1, 2, 6]. This current appears to be caused by an internal SAMPH and hDAT interaction [2]. We have built a functional model of hDAT with two binding
sites for STPs: an extracellular site that opens the transporter-channel, and an intracellular site that
holds the transporter open after external S-AMPH is removed and is responsible for the persistent
current; this mechanism is referred to as a molecular stent [2]. The location of interaction site(s) is
an ongoing project in our laboratory utilizing the structure of the Drosophila DA transporter,
dDAT [41] to build and test an hDAT homology model. The data we have gathered strongly
9

supports the idea that hDAT currents play a significant role in neuronal excitability and
consequently in transmitter release.
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Figure 4: hDAT currents hDAT expressing Xenopus oocytes voltage clamped to -60 mV. All
drug applications are of 10 µM concentration. DA perfused outside for 60 s (horizontal bar
above trace) induces inward depolarizing current (IDA) that returns swiftly to baseline upon
removal. 60 s application of S-AMPH produces similar size peak current (ISTP); however, after
washout, the current establishes a new baseline below the original value, called persistent
current (IPC). This IPC is hDAT-mediated since it is blocked by addition of COC. In addition,
COC reduces/eliminates the constitutive leak current (IL) associated with hDAT insertion in the
cell membrane, which appears as an outward deflection in the current trace.
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1.5. DAT substrate type psychostimulants- STPs

Psychostimulants cause hyperactivity, euphoria, and cardiovascular effects [42, 43]. The
elevation of mood and the subsequent drug seeking behavior associated with psychostimulants are
mediated by increased levels of DA in the nucleus accumbens (mesolimbic reward circuits) that
stimulate dopamine receptors [44, 45]. A number of psychostimulants such as amphetamine
(AMPH) and methamphetamine (METH), abbreviated as STPs (substrate type psychostimulants),
are DAT substrates [1, 6, 46]. These compounds mimic the action of the endogenous
neurotransmitter DA and are transported into the presynaptic cell via DAT, producing an inward
depolarizing current at the resting membrane potential [1, 2, 6, 47]. DAT substrates, including DA
itself, cause DA release [48-52]. This substrate-induced release is partially attenuated by the
presence of voltage-gated sodium channel blockers like tetrodotoxin (TTX); it is also partially
affected by external Ca2+ manipulation, but pretreatment with gamma-butyrolactone (an inhibitor
of dopaminergic cell firing) fails to alter DA release [48, 52, 53]. There are several proposed
mechanisms for the STP-induced DA release: 1) exocytotic DA release [2, 24, 44, 54], 2)
facilitated exchange [55], 3) weak base DA depletion from synaptic vesicles [56, 57], and 4)
reverse transport [58]. These mechanisms are not mutually exclusive, and abundant experimental
evidence exists for each one. Ingram et al. and Saha et al. show that in midbrain dopaminergic
neurons, AMPH-induced depolarizing currents increase cell excitability and thereby exocytotic
DA release [24, 59]. Likewise, in 2011 Ramsson et al. demonstrated action potential-dependent
dopaminergic neurotransmission by AMPH in anesthetized rats [44], while Daberkow et al.
showed equivalent results in ambulatory rats [54]. Meanwhile, in a study by Jones et al., it is
pointed out that in DAT homozygous knock-out mice, DAT’s presence is essential for substrateinduced DA efflux into the extracellular space [18]; in the DAT -/- mice study, AMPH decreases
12

stimulation-dependent DA release, which is an exocytotic process. On the other hand, after
increase of cytoplasmic DA, there is no increase of extracellular dopamine, implying the necessity
of AMPH-bound DAT for reverse transport of neurotransmitters [18]. Furthermore, Sulzer et al.
found AMPH reduces DA quantal size due to redistribution of DA in the cytosol [57]. Thus
evidence exists for both exocytotic and reverse transport as mechanisms for substrate-induced DA
release.
Although the dopaminergic system is established as the site of action of psychostimulants,
it is well known that many compounds also affect the serotonergic system which is important
modulator of behavioral effects. Thus, psychostimulants can produce both DA-mediated, abuserelated effects and 5-HT-mediated, abuse limiting effects [3, 60]. Furthermore, studies show that
releasers that are equipotent at DAT and SERT have minimal abuse liability and suppress drugseeking behavior, especially promising appears the 30-fold selectivity of DA vs. 5-HT release [46,
61].

1.5.1. Amphetamine and methamphetamine

Amphetamine and methamphetamine (METH) are homologues of phenethylamine and are
the parent compounds of a wide range of psychoactive derivatives. These stimulants increase
locomotion and focus, and decrease appetite and food intake [62-64]. Both AMPH and METH
have strong reinforcing properties evidenced in self-administration animal studies [65, 66] and
high abuse liability assessed by intracranial self-stimulation (ICSS) [60]. Their primary effect is
through DAT, demonstrated in DAT knock-out or knock-down mice who exhibit reduced or no
sensitivity to the psychostimulants [16, 18, 67-70]. Using in vitro synaptosomal release studies,
both compounds are shown to release all monoamines; however, they exhibit much greater potency
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for DA and NE than 5-HT [46]. AMPH and METH appear to be substrate to hDAT as they induce
inward current through the transporter at physiological potential. In addition, the S- enantiomers,
S-AMPH and S-METH, produce an inward persistent current at hDAT after their wash out [2, 6].
AMPH’s and METH’s intake can results in schizophrenia-like symptoms and fatal toxicity [71].
Paradoxically, AMPH appears useful in the treatment of conditions such as attention-deficit
hyperactivity disorder (ADHD), narcolepsy, and obesity [72-74].

1.5.2. Synthetic cathinones

The beta-keto amphetamine, cathinone (CATH), is the primary active ingredient of the
khat plant (Catha edulis) found in East Africa and the Arabian Peninsula [75]. Fresh leaves of this
shrub contain CATH, which is often referred to as a “natural amphetamine” since it possesses
amphetamine-like psychostimulant properties. The synthetic cathinones appear under numerous
names (bath salts, plant food, insect repellant, and brand names such as red dove, zoom, ivory
wave, vanilla sky etc) [76, 77]. Similar to AMPH, cathinone derivatives have psychoactive effects
due to their action at the monoamine systems [75, 78-80]. In drug discrimination studies, CATH
and N-methylated cathinone, methcathinone (MCAT), substitute for AMPH and METH and
exhibit greater potency than METH or AMPH, with MCAT being more potent than CATH [79].
MCAT releases DA similar to AMPH and facilitates intracranial self-stimulation studies (ICSS)
which shows its high abuse liability [3, 81]. A para-methylated MCAT, mephedrone (MEPH), is
another cathinone derivative that has gained popularity in recent years in Europe and USA [78, 82,
83]. In vitro synaptosomal uptake inhibition studies and in vivo microdialysis and intracranial selfstimulation (ICSS) studies in rat brain reveals a mixed effect at both serotonergic and
dopaminergic systems [3, 84]. Electrophysiological assays additionally imply that MCAT and
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MEPH are substrates for DAT as they induce inward currents at physiological potentials under
voltage clamp conditions [1, 6]. Similar to S-AMPH, the two cathinones S-MCAT and MEPH
elicit persistent current, IPC, at hDAT which we hypothesize alters subsequent DA exposure at
DAT and neuronal excitability [1, 2, 6].
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1.6. DAT reuptake inhibitors

Cocaine (COC) is a naturally occurring alkaloid from the Erythroxylon coca plant abused
for many years due to its psychostimulant effects [85]. Cocaine has several different target proteins
in the brain such as DAT, SERT, norepinephrine transporter (NET), sodium channels and perhaps
others [17, 86]. For many years the mechanism for its strong reinforcing effects was unknown. In
the 1987 publication of Ritz et al., cocaine was identified to exhibit its action mainly through
binding to DAT and inhibition of DA uptake in rat striatal tissue [17]. In behavioral animal studies,
lesions in the mesolimbic dopaminergic projection inhibited self-administration of cocaine in rats
[17]. Similar to STPs, such as AMPH, COC increases DA extracellular levels. Unlike STPs,
however, COC is not transported into the cell but rather exerts its actions through a blockade of
the transport pathway within DAT. This “cork in a bottle” mode of action results not only in uptake
inhibition and increased DA synaptic levels but also in reduction/elimination of ionic fluxes
through the transporter [1, 6, 23]. Current recordings in voltage clamped Xenopus oocytes reveal
COC blocks IL, which is present in DAT in the absence of substrate. Furthermore, COC also
inhibits IDA, ISTP, and IPC [1, 6, 23]. COC’s block of inward constitutive leak and substrate-induced
peak currents, as mentioned previously, appears as an outward deflection of the current trace under
voltage clamp conditions.
Physiological and anatomical changes ensue upon repeated cocaine exposure. Chronic
cocaine administration in rats causes an increase in dendrite branching and spine density in the
nucleus accumbens [62, 87]. Furthermore, prolonged exposure to cocaine in animals (rats, rhesus
monkeys etc.) shows increased H3DA uptake but unchanged Km indicative of DAT insertion in the
plasmalemmal membrane from the endosomal recycling pool, a finding substantiated in
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postmortem human cocaine addict subjects [39, 88]. Uptake inhibitor induced up-regulation is
opposite to the effect observed with substrates, which result in DAT down-regulation.
A synthetic cathinone, 3,4-methylenedioxypyrovalerone (MDPV) has gained tremendous
popularity and is now a Schedule I drug as of October 2011 [89]. It is a central stimulant that,
unlike CATH or MCAT, increases DA by acting as a reuptake inhibitor similar to COC [1, 6, 90].
Fatal overdoses of MDPV and its dominance in the seized bath salts mixtures have brought
attention to its exact mechanism of action [91].
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1.7. DA transients in the action of abused drugs

Electrophysiological studies of excitability in dopamine neurons show a unique action
potential (AP) waveform: a long AP duration and a pronounced after AP hyperpolarization [92].
These neurons have a tonic (pace-making) activity (2-10 Hz) and a phasic or burst activity (15-30
Hz) [92]. The tonic activity gives rise to background levels of DA in the 5-20 nM range, while the
bursting events raise extracellular levels of neurotransmitter to the low micromolar range [93].
When association between cues and reinforcers is established (both natural and drug related
reinforcers) the cues stimulate burst firing and phasic DA release. The burst firing and transient
extracellular DA augmentations require activation of high-voltage activated Ca2+ channels which
in turn leads to calcium-activated potassium channel opening to end the bursting activity [94].
These DA transients are observed in expectation of natural rewarding experience or upon
unexpected reward delivery and are associated with goal-directed behaviors. In addition, after
reward delivery, there is a second effect that depends on the reward prediction error [95]. If the
reward prediction error is positive, the expected reward is smaller than the obtained (better than
expected), an additional increase of firing above the tonic level is observed. Negative reward
prediction error, the expected reward is greater than what is obtained (worse than expected), causes
a transient pause or silencing below the tonic level in neuronal firing results [96]. This reward
prediction error is used to modulate reward expectations and it plays a role in the synaptic
rearrangement to strengthen or weaken glutamatergic and GABAergic synapses onto
dopaminergic neurons.
Using in vivo microdialysis, increases in extracellular DA levels due to phasic/burst firing
are measured and compared to the tonic basal levels. Studies employing this technique reveal the
action of abused psychostimulants to cause dramatic augmentations in DA in the NAcc, much
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greater than natural rewards (food, sex). The exaggerated rise of DA is absent when drugs with no
abuse liability are administered to the tested subjects. Often there is a cross talk between
psychostimulants and several different cellular targets. For example, METH can release both DA
and 5-HT; however, the selectivity for one neurotransmitter over the other is of great importance.
Monoamine releasers with greater selectivity for DA over 5-HT produce more abuse-related
behaviors, hence, the and the ratio of extracellular concentration of DA/5-HT is established as a
good indicator for abuse liability [46, 97-99]
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1.8. Ca2+ channels and excitability

Voltage-gated ion channels play a major role in many excitable cells: they do not only
affect the membrane potential of the cell but also trigger a number of other effects such as
neurotransmitter release, gene expression, certain kinases activation etc. [100]. The L-type Ca2+
channels (CaV1) are important modulators of signal transduction and excitability in excitable cells
[94, 101, 102]. Their current is distinguished by large single channel conductance (compared to
the other types of CaVs), high voltage of activation, and slow voltage inactivation hence it is long
lasting [103]. They are localized primarily in the cell bodies and dendrites of neurons as compared
to CaV2 (N, P, Q-types) which are located in synaptic densities and involved in vesicular fusion
[104]. The N-type of CaVs (Cav2.2) have an intermediate rate of inactivation compared to other
Cav types, however the voltage dependence and current can be highly variable depending on the
subunit composition and neuronal identity [103, 105]. While Cav2.2 are reported to directly
interact with SNARE proteins and entry of Ca2+ through the channels triggers vesicular fusion,
CaV1.3 is implicated in pace-maker neurons, including some dopaminergic neurons and
neuroendocrine cells like adrenal chromaffin cells [106, 107]. Since L-type Ca2+ channels (CaV1.2
and CaV1.3) are co-expressed with monoamine transporters in several types of excitable cells [94,
108], determining a functional interaction between these two classes of proteins could constitute
an additional molecular mechanism of STP action. Previous studies using HEK 293 coexpression
of L-type Ca2+ channel CaV1.3 or N-type Ca2+ channel CaV2.2 and hSERT show there is electrical
coupling between the CaV1.3 and hSERT which was not observed with CaV2.2 and hSERT under
the same conditions [109].
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1.9. The objective of the present study

The overall goal of our studies was to elucidate the biophysics of reuptake inhibitors and
STPs as they modulate the function of DAT and to uncover their physiological relevance in
neuronal excitability. We specifically focused on two crucial elements of STP mechanisms: 1)
characterizing the biophysical properties of ISTP and IPC, and 2) measuring the effect of ISTP and
IPC on excitability in dopaminergic neurons. We hypothesized that the long-lasting IPC will cause
a moderate but persistent depolarization in DA neurons that will prolong neuronal depolarization
and increase both excitability and vesicular DA release, thereby raising synaptic DA concentration
and increasing reward-directed behavior.
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Chapter 2 MATERIALS AND METHODS

2.1. Expression of hDAT in Xenopus oocytes

Oocytes were harvested and prepared from adult female Xenopus laevis following standard
procedures [110]. Stages V–VI oocytes were selected for cRNA injection within 24 h of isolation.
cRNA was transcribed in the pOTV oocyte transcription vector (gift of Mark Sonders, Columbia
University) using Ambion mMessage Machine T7 kit (Ambion Inc., Austin, TX, USA). Each
oocyte was injected with 40 nL of 1 μg/ μL hDAT cRNA (final amount 40 ng) (Nanoject
AutoOocyteInjector, Drummond Scientific Co., Broomall, PA, USA) and incubated at 18°C for
6–10 days in Ringers solution supplemented with NaPyruvate (550 μg mL−1), streptomycin
(100 μg mL−1), tetracycline (50 μg mL−1) and 5% dialyzed horse serum.

2.2. Two-electrode voltage clamp
Electrodes had resistances from 1 to 3 MΩ. Xenopus oocytes expressing hDAT were
voltage clamped to −60 mV (unless otherwise noted), and buffer was gently perfused until a stable
baseline was obtained, then the experimental substrates were perfused until stable currents were
obtained, or for time periods indicated. The voltage clamp apparatus used for these experiments
was a Gene Clamp 500 Amplifier and a 16 bit A/D converter (Digidata 1320A, Axon Instruments).
Data were sampled at 5 kHz and digitally stored for off line analysis using Clampfit 10.2 software
and 1-kHz filtering. Inward and outward drug-induced currents were compared with holding
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currents required for voltage clamp at −60 mV in the absence of drugs. Currents varied in size;
however, oocytes with −20 to −60 mV resting potentials and 10 µM DA responses of 20 nA to 100
nA were selected for the analysis. To measure drug-induced I(V) curves, we first generated an I(V)
curve for buffer without drug, which we then subtract from I(V)s for buffer with drug. Buffer
subtracted I(V) curves for 10 mM DA, MEPH-peak, MDPV and COC were generated under
voltage clamp between −100 and +20 mV. To normalize I(V) curves, we set the 10 μM DAinduced current to 100 at −100 mV in each oocyte [1, 2].

2.3. Solutions for Xenopus oocytes

Extracellular (in mM): 120 NaCl, 7.5 HEPES, 5.4 K Gluconate, 1.2 Ca Gluconate,
pH adjusted to 7.4 with NaOH. Intracellular electrode: 3 M KCl. The speed of solution exchange
was 4 mL min−1. No drug used in this study had any effect in non-injected oocytes (data not
shown). See also Rodriguez-Menchaca et al [2].

2.4. Materials

Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV) were prepared as their
hydrochloride salts and purified to homogeneity. S(+)Methamphetamine and S(−)methcathinone,
as their hydrochloride salts, were available from a previous investigation and were purified to
homogeneity. Cocaine hydrochloride was obtained from the NIDA drug supply program.

2.5. Culture of HEK 293 cells
Transiently expressed hDAT HEK 293 cells (HEKhDAT cells) were prepared in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM Lglutamine, penicillin (100 units/ml), and streptomycin (100 g/ml) [111]. Wild type hDAT cDNA
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subcloned in pIRES2 DsRED-Express2 (Clontech) were used to transfect HEK 293 cells via
lipofectamine 2000 (GIBCO BRL). Cells were grown for 48-72 h before measurements. Since
expression plasmid codifies the red fluorescent protein (DsRED) the transfected cells were
identifiable at the red channel: excitation 550/15 nm and emission 620/60 nm.
2.6. Generation of Flp-In Trex cells expressing hDAT
The generation of the hDAT stable inducible cell line (FlphDAT) was done using the FlpInTm T-RexTM 293 system (Invitrogen). The hDAT cDNA (accession number: NM_001044) was
subcloned into pcDNA5/FRT/TO plasmid and the targeted recombination and cell selection were
performed as described previously [112]. Flp-hDAT cells were grown in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum. hDAT expression was induced with
doxycycline (1μg/ml) at least 3 days before each experiment. The Ca2+ channels used in this study
were CaV2.2 (α1B, Addgene #26570), CaV1.3 (α1D, Addgene # 26571), CaV1.2 (α1C accession
number: NM_001136522), β3 (Addgene #26574) and α2δ1 (Addgene #26575). All plasmids were
kindly provided by Dr. Diane Lipscombe (Department of Neuroscience, Brown University,
Providence, Rhode Island, USA) except CaV1.2 that was kindly provided by Dr. Manfred Grabner
(Department of Medical Genetics, Molecular, and Clinical Pharmacology, Innsbruck Medical
University, Innsbruck, Austria). The CaV1.2 cDNA was subcloned into pcDNA6 expression
plasmid thus all α1 subunits are expressed under the same background vector. In addition EGFP
expression plasmid was used as transfection marker. The cells were co-transfected with the DNA
ratio α1:β3:α2δ1:EGFP=1:1:1:0.2 using Fugene 6 (Promega) as transfection reagent.
2.7. Whole cell patch clamp and electrophysiological recordings
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Cells were cultured on 12 mm round glass coverslips (Fisher Brand) for 1-2 days before
measuring currents. Coverslip was placed on a stage of Olympus IX50 inverted microscope for
whole cell recording configuration. Patch pipettes with resistance ranging from 3 -6 MΩ made
from borosilicate glass capillary tubing and coated with Sylgard (Dow Chemicals) were filled with
133 K Gluconate, 5.9 NaCl, 1 CaCl2, 0.7 MgCl2, 10 EGTA, 10 HEPES, pH adjusted to 7.2 with
KOH. The cells were continuously superfused with external solution containing 130 NaCl, 4 KCl,
2 CaCl2, 1 MgCl2, 10 HEPES, 10 Glucose, pH adjusted to 7.4 with NaOH. Patch clamp recording
at T=35°C (AutoMate Scientific) were performed using an Axopatch 200A amplifier (Molecular
Devices) and currents were acquired using Clampex 8.2 software (Molecular Devices). The
voltage was clamped at −60 mV unless otherwise noted and drugs were applied for 5 s at various
concentrations following a 30 µM DA pre-pulse. Current traces were acquired at 1 kHz. Holding
currents for all traces were subtracted and DA pre-pulse was normalized to 1 for cell to cell
comparison.
2.8. Experimental solutions
Extracellular (in mM): 130 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 Glucose, pH
adjusted to 7.4 with NaOH. Intracellular electrode: 133 K Gluconate, 5.9 NaCl, 1 CaCl2, 0.7
MgCl2, 10 EGTA, 10 HEPES, pH adjusted to 7.2 with KOH.
For Ca2+-free imaging recording we used the following extracellular solution (in mM): 130
NaCl, 4 KCl, 2 MgCl2, 10 HEPES, 10 Glucose, 2 EGTA, pH adjusted to 7.4 with NaOH.
2.9. APP+ uptake assay
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4-(4-(Dimethylamino)phenyl)-1-methylpyridinium (APP+), a fluorescent substrate of
hDAT, was used to monitor hDAT activity by fluorescence microscopy as previously described
[111]. Cells grown on 96 well imaging plates were placed on the stage of the fluorescence
microscope describe above. The wavelengths used to detect the APP+ signal were 460/10 nm for
excitation and 535/50 nm for emission.
2.10. Ca2+ current-voltage dependence determination
The Ca2+ currents were determined in HEK 293T cells transfected with CaV1.2, CaV1.3 or
CaV2.2 as described previously [112]. The external solution used was (in mM): 155
tetraethylammonium (TEA)-Cl, 5 CaCl2, 10 Hepes, pH 7.4 with TEA-OH. The internal solution
composition was (in mM): 130 CsCl, 10 Cs-EGTA, 1 CaCl2, 4 MgATP and 10 HEPES, pH
adjusted to 7.3 with CsOH. The effective serial resistance was corrected to 80% using the built-in
circuit of the Axopatch 200B amplifier. The leak current was subtracted using a –P/6 protocol. The
microelectrodes were made from 8520 glass capillary (Warner Instruments, #64-0817), fire
polished, and Sylgard coated. The electrodes tip resistance was ~2.5 MΩ when filled with the
internal solution.
2.11. Intracellular Ca2+ determination
The intracellular Ca2+ determinations were done using the Ca2+ sensitive dye Fura-2AM
and visualized in an epifluorescence microscope following the procedure and using the equipment
described previously [112]. The measurements were done at constant perfusion at 35°C. The Fura2 signal was acquired switching the excitation wavelength between 340/10 to 380/10 nm using a
monochromator as described previously [112], dichroic mirror 490LP and an emission filter
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510/40 nm. The acquisition frequency was 1Hz. All images were background subtracted and the
Ca2+ signals are shown as F340/380/F0. In the case of dose-response experiments the test values were
normalized by the mean of the maximal value of control DA pre-pulse.

2.12. Immunofluorescence

Sample fixation and labeling was performed as described earlier [113]. The primary
antibodies used were rat monoclonal anti-DAT (Santa Cruz Biotechnology, Cat# sc-32258) with
secondary antibody used Alexa Fluor 555 goat anti-rat IgG (Invitrogen, Cat# A21434) and primary
rabbit polyclonal anti-Pan NaV (Alomone Labs, Cat# ASC-003) with secondary antibody Alexa
Fluor 488 goat anti-rabbit IgG (Invitrogen, Cat# A11008). The nuclei were stained with DAPI.
The specimens were visualized either in a Zeiss 710 confocal microscope.

2.13. Western Blot

Total protein extracts were run in SDS-PAGE in duplicates. One gel was stained with
Coomasie blue staining for total protein visualization and the other was electrically transferred to
a PVDF membrane. To detect hDAT expression, the membrane was incubated in anti-hDAT
monoclonal rat antibody and then exposed to secondary antibody conjugated with horseradish
peroxidase. The hDAT band was visualized by chemiluminescence using RapidStep ECL Reagent
(Calbiochem) and the images were acquired in a digital imaging system (FluorChem E, Protein
Simple, Santa Clara, CA).

2.14. Maintaining LUHMES
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Nunclon (Nunc, Roskilde, Denmark) plastic cell culture flasks and multi-well plates were
pre-coated with poly-ornithine 50 µg/mL overnight. After H2O wash and dry, 1 µg/mL fibronectin
was applied for 3 hrs. (Sigma-Aldrich, St. Louis, MO, USA). After removal of the coating solution,
culture flasks were washed once with H2O and air-dried before cell seeding. Proliferation medium
consisted of Advanced Dulbecco’s modified Eagle’s medium/F12 supplemented with 1% N-2
supplement (Invitrogen, Karlsruhe, Germany) and 40 ng/mL recombinant basic fibroblast growth
factor (bFGF) (R&D Systems, Minneapolis, MN, USA). For differentiation, we used F12, 1% N2 supplement, 1 mM dibutyryl cAMP (Sigma-Aldrich), 1µg/mL tetracycline (Sigma-Aldrich) and
2 ng/mL recombinant human GDNF (R&D Systems) [114].

2.15. Quantitative PCR
Total RNA was prepared with TRIzol (Invitrogen), and 1 μg RNA was reverse-transcribed
with a High Capacity cDNA Archive kit (Applied Biosystems). The abundance of mRNA levels
was assessed with premixed primer-probe sets and TaqMan Universal PCR Master Mix (Applied
Biosystems). The cDNA for the target genes was left undiluted while the gene encoding GAPDH
was diluted 10x and then was amplified with an ABI 7900HT cycler. Gene expression was
normalized to that of the gene encoding GAPDH [115].
2.16. Statistics
Summary TEVC and patch clamp data are reported as mean ± SEM; n denotes the number
of cells and each cell tests one condition. Mean currents are expressed as test current normalized
to DA pre-pulse to account for differences in hDAT expression level. Statistical analysis was
executed using Origin 8 and Prism 5 (GraphPad).
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Chapter 3 RESULTS

3.1. Conduction states in hDAT

3.1.1. Structures

Figure 5 shows the chemical structures of DA, as well as S-, and R- stereoisomers of
AMPH, S-METH, S-CATH, S-MCAT, MEPH, MDPV, and COC. The top row compares the
structures of the most commonly used psychostimulants for the treatment of ADHD and
narcolepsy. It also illustrates the spatial orientation differences in the enantiomers of AMPH as
well as S-METH. The bottom row shows the chemical structures of synthetic analogues of the
naturally occurring cathinone: MCAT, MEPH, and MDPV. All of these compounds are analogous
to AMPH or METH with the addition of a β-keto group. The cathinone analogues are components
of bath salts which is common drug mixture with extensive web-based marketing [77, 116]. It is
noteworthy that drugs found on the clandestine market are racemic mixtures comprised of equal
amounts of their S- and R-enantiomers. On the other hand, pharmaceutical compounds are
composed of specific ratios of enantiomers as in Adderall which is composed of 75% S- and 25%
R-AMPH and is used to treat ADHD and narcolepsy [51, 117].

29

Figure 5: Chemical structures of DA and STPs Top row shows structural similarities among
DA and the S- and R- isomers of AMPH and METH. Bottom row compares chemical structures
of S-CATH and the cathinone analogues S-MCAT, MEPH, and MDPV which are common
ingredients of bath salts.

30

3.1.2. Dopamine, STPs, and reuptake inhibitors differentially affect hDAT

Figure 6 displays currents elicited by the compounds illustrated in Fig 5. Xenopus oocytes
expressing hDAT were exposed to substrates and reuptake inhibitors (10 µM, a saturating
concentration, -60 mV) for 1 min. Room temperature perfusion of DA stimulated an inward current
(IDA) that rapidly decayed to the original baseline upon wash out. Under the same conditions, all
STPs S-AMPH, R-AMPH, S-METH, S-MCAT, and MEPH induced a qualitatively similar inward
peak current (ISTP). Intriguingly, a persistent current was observed for minutes after STP removal
(IPC) in all S-isomers (S-AMPH, S-METH, S-MCAT) and the racemic MEPH. The IPC/ISTP ratio
varies widely among compounds. All traces of STPs are normalized to ISTP=1 for visual
comparison. The reuptake inhibitors COC and MDPV evoked outward currents which are actually
the inhibition of an inward constitutive leak current (IL) through hDAT [1, 6, 23]. MDPV produced
a larger outward current deflection as compared to COC, indicating that COC does not fully inhibit
the leak through hDAT. Figure 7 is illustrative of the response of STPs used in this study.
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Figure 6: DA, STP, and reuptake inhibitor-induced currents at hDAT Sample currents
generated in hDAT by 60 s. application of 10 μM dopamine (DA), S-amphetamine (S-AMPH),
R-amphetamine (R-AMPH), S-methamphetamine (S-METH), S-methcathinone (S-MCAT),
mephedrone (MEPH), cocaine (COC), and 3,4-methylenedioyyrovalerone (MDPV) at −60 mV.
All STP traces are normalized to the same peak size for comparison. COC and MDPV of
oocytes with similar DA pre-pulse were used to illustrate the different levels of inhibition of
the two compounds.
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3.1.3. The potency and efficacy of ISTP at hDAT varies
In order to study STP’s ability to induce hDAT currents we conducted dose-response
studies (Figure 7). hDAT-expressing oocytes were exposed to 10 µM DA pre-pulse followed by
various drug concentrations at −60 mV. In Figure 7, summary of drug-induced responses are
represented as a percentile of 10 µM DA pre-pulse (DA= 100%). All examined STPs were in their
more potent S-stereoisomer form with the exception of MEPH (the racemate was used, as in
clandestine samples) [80, 118]. Dose response curves were fit to Hill 1 equation using Origin 8:
𝑥𝑛
𝑦 = 𝑆𝑇𝐴𝑅𝑇 + (𝐸𝑁𝐷 − 𝑆𝑇𝐴𝑅𝑇) 𝑛
𝑘 + 𝑥𝑛
where x is the concentration of the tested compound, Y is the response measured, START is min
response and END is the maximal response, k is the concentration that yield half–maximal
response, and n is the Hill slope parameter.
The order of potency (EC50) was S-MCAT (0.23 ± 0.03 μM, n=5) > S-METH (0.64 ± 0.15
μM, n≥5) > MEPH (0.84 ± 0.14 μM, n=5) > S-AMPH (1.21 ± 0.15 μM, n≥5, data not shown). In
terms of efficacy, S-AMPH (118 ± 7%, n≥5, data not shown) and S-METH (107 ± 6%, n≥5)
produced the greatest inward current followed by S-MCAT (57±1%, n=5) and MEPH (41 ± 1%,
n=5). An important note here in comparing these values is that MEPH used was a racemic mixture
(50% S- and 50% R- enantiomer), therefore the values for EC50 and Vmax obtained from this studies
are likely right and down shifted respectively. Here we did not explore STP’s ability to induce
IPC: that will be investigated in later section.
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Figure 7: Dose-response curves of STPs (Figure adapted from [6]) Dose–response curves
(±SEM) for S-METH, S-MCAT, and MEPH in hDAT expressing Xenopus oocytes at −60 mV.
Data points were obtained by exposing hDAT-expressing oocytes to different concentrations
of drug for 1 min and normalizing peak currents to a 10 µM DA pre-pulse (n ≥ 5).
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3.1.4. Difference in efficacy but not potency of MDPV and COC to inhibit constitutive hDAT
current

As seen in Figure 6, unlike other tested cathinone analogues MDPV did not produce an
inward peak current. In contrast, MDPV induced an outward current similar to that observed with
COC, which indicated that MDPV is not transported but, rather, it is a reuptake inhibitor.
Compared with COC, we observed a larger outward current upon application of MDPV and
constructed a full dose-response curve for hDAT constitutive leak inhibition for both (Figure 8).
MDPV was more efficacious than COC in inhibiting hDAT’s constitutive leak current (32.9 ± 1.9
and 24.6 ± 0.5 % of DA pre-pulse respectively, n=5). Interestingly, both compounds had similar
potency (0.33 ± 0.07 μM and 0.30 ± 0.04 μM respectively, n=5) to inhibit hDAT’s endogenous
leak, IL. Because these reuptake inhibitors inhibit different magnitude of leak currents, we may
think of them as full or partial inverse agonists when discussing hDAT-induced currents.
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Figure 8: COC and MDPV dose-response curves (Figure adapted from [6]). Different
concentrations of MDPV or COC were applied to hDAT-expressing Xenopus oocytes voltage
clamped at −60 mV (n=5 for each concentration). Drug responses are normalized to a 10 µM
DA pre-pulse.
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3.2. Action of reuptake inhibitors at hDAT
3.2.1. Reuptake inhibitors block different levels of hDAT’s constitutive leak current

In Figure 6 and Figure 8 we see the synthetic cathinone MDPV induces a larger upward
current deflection than COC. As mentioned previously, reuptake inhibitors do not produce a net
outflow of positive charge at -60 mV; rather, they decrease the net inward current through hDAT.
Because a larger outward deflection occurs upon blockade by MDPV, we conclude that COC does
not block all of the constitutive leak. To eliminate possibility of endogenous oocyte conductance
inhibition by the blockers, both COC and MDPV were applied to uninjected oocytes: no deflection
from original baseline current level was observed in either case (data not shown).
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3.2.2. MDPV has the electrophysiological signature of a tight binding reuptake inhibitor

To compare the potency of COC and MDPV to inhibit IDA, we competed 5 µM DA with
various concentrations of the two compounds (Figure 9A and 9B, respectively). Both compounds
either reduced or eliminated the dopamine-induced current. Interestingly, while COC application
inhibited IDA within 15-30 s., MDPV blockade of the dopamine-induced inward current never
reached a steady state within the timeframe of the experiment which made it impossible to obtain
an IC50 value for MDPV. For the high concentrations (10 µM), steady state was achieved within
15 s. Lower concentrations of MDPV (0.5 µM) reached steady state at 5 min post application (see
slow inhibition of DA-induced current in panel B).
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Figure 9: COC and MDPV blockade. (Adapted from [6]) Xenopus oocytes voltage clamped
to −60 mV A) Raw traces for cocaine (COC) dose–inhibition curve: 5 μM dopamine (DA)
applied for 30 s (solid line) followed by perfusion of 5 μM DA plus various concentrations of
COC (dashed line). B) Raw traces for MDPV dose–inhibition under the same conditions as A.
Unlike COC, MDPV inhibition did not reach a steady state level within 1 min. The inhibitory
effect at all MDPV concentrations persisted until maximum inhibition was reached (for the
lowest concentrations, 0.5 μM, it takes more than 5 min to reach steady state; in contrast, the
highest concentration of MDPV (10 μM) reaches the steady state in 15 s).
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3.2.3. Time course of COC and MDPV block in oocytes

In Figure 10A, 10 µM MDPV was applied during 10 µM MEPH-induced IPC. After MDPV
was removed, the baseline remained elevated (block of hDAT’s constitutive leak) for an extended
period of time. Under the same conditions, 10 µM COC caused a block of hDAT currents only for
the duration of its application (Figure 10B). To better characterize the differences between these
two reuptake inhibitors, we designed a protocol to quantify DAT’s recovery after exposure to the
blocker. We applied a 30 s DA pre-pulse to estimate DAT’s expression level. Next, we applied
either COC or MDPV for 1 min to block the constitutive leak current. Finally, to monitor recovery
after block, we measured the DA-induced current at 1, 5, 10, 15, 20, 25, and 30 min following
blockade. To account for transporter down-regulation due to numerous substrate applications, we
did a control measurement without blocker and applied DA pulses at the same time points as in
the experiment shown in Figure 10C-D. The observed decrease in the IDA control was used to
normalize the results in the blocker-applied measurements. Raw traces for each blocker are shown
in Figure 10C. Each experiment was repeated three times at each concentration. The summary plot
shown in Figure 10D illustrates the dramatic differences in the time course of inhibition of MDPV
compared with COC. Whereas all MDPV concentrations tested caused at most 10% recovery of
hDAT currents 1 min post blocker application, all COC concentrations tested showed immediate
recovery at equivalent time points. MDPV’s action was difficult to wash off on this time scale and
even 30 min after inhibition, only 40% recovery occurred following blockade at lower
concentrations (1 and 3 µM) and only 20% recovery occurred after 10 µM MDPV. Although
modest recovery from MDPV begins at 10 min, we cannot distinguish between hDAT recovery
and new copies of hDAT inserted into the membrane. Because uptake inhibitors up-regulate
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hDAT, the recovery after MDPV block may be due to new hDATs inserted into the membrane,
which correlates with recovery after COC block.
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Figure 10: MDPV and COC blockade reversibility. (Adapted from [1]) Panels A) and B)
show raw traces of 60 s blocker application (MDPV or COC, 10 µM) during IPC induced by 60
s MEPH external application (10 µM) at V = -60 mV C) At V = -60 mV, 30 s exposure of 10
µM DA is followed by 60 s application of 10 µM COC (top) or MDPV (bottom). 30 s pulses
of DA follow the block at time in min: 1, 5, 10, 15, 20, 25, 30 (25 and 30 min not shown) D)
Cumulative data from C), n = 3. Recovery of IDA after block is plotted on the y-axis. One minute
after COC treatment (10 and 30 µM), the DA-induced current recovers completely. One minute
after MDPV treatment (1, 3, 10 µM), the DA-induced current recovers only 10% of its initial
value. At 30 min, recovery from MDPV is 50, 50 and 20%, respectively.
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3.2.4. MDPV reversibility in mammalian expression system

We tested MDPV’s long lasting effect at hDAT expressed in HEK 293 cell at physiological
temperature (T= 37ºC) using fluorescent microscopy. First, 2 µM APP+ was applied for 3 min to
establish a stable rate of uptake. Next, either 10 µM DA (black trace) or MDPV (red trace) was
applied to compete the APP+ uptake (flat portion of Figure 11A). Lastly, 2 µM APP+ was reapplied
to monitor the off rates of DA and MDPV. We define full recovery as rate of uptake after block
being equal to the pre- DA and pre-MDPV rate of uptake. For times greater than 400 s, the two
traces in Figure 11B have different shapes, illustrating the differences in off rates of each
compound. Since we cannot determine the exact recovery point, we show the same data in 11A
but converting APP+ uptake into rate of uptake by taking the 1st derivative of the two traces. Figure
11B compares the rates of APP+ uptake following DA and MDPV application. Arrowheads
emphasize rate differences between the two drugs. This distance between the arrowheads indicate
300 s or 5 min; that is, it takes 5 min for hDAT to recover after MDPV block vs. 30 s after DA
inhibition of APP+ uptake. The inhibitory effect in oocytes is at least 6 times longer than in HEK
293 cells. However, there are a few differences that can account for the differences. First, we have
different expression systems with difference in membrane and protein composition. In addition,
the perfusion in oocytes is at room temperature while the HEK 293 cells is at 35ºC. Furthermore,
in oocytes, we measure IDA to determine hDAT function recovery at -60 mV, while in HEK 293
cells we monitor the ability of hDAT to transport fluorescent substrate APP + without voltage
clamp.
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Figure 11: MDPV long action in hDAT expressing HEK 293 cells A) 2 µM APP+ is applied
for 3min to hDAT expressing HEK 293 cells, T= 37ºC to establish a stable uptake rate. Either
10 µM DA (black trace) or MDPV (red trace) is then applied with 2 µM APP + to observe the
competitive inhibition of the fluorescent substrate. Following the inhibition, APP+ was
reapplied for 10 min to observe the off kinetics of DA and MDPV B) To quantify the difference
of off kinetics of DA and MDPV, rate of uptake (1st derivative) of APP+ uptake was plotted
against experiment progress in time.
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3.2.5. Action of bath salts mixture

In the past few years, a number of synthetic cathinones have invaded the clandestine market
[83] under the name bath salts. In most samples a mixture of several compounds was identified,
including cathinone analogues, cocaine, caffeine, THC, and other compounds [83]. MEPH and
MDPV are among the more popular ingredients (Fig. 1) and were placed on Schedule I in October
2011 [89]. Bath salts are easily obtainable in head shops and on the Internet in packages clearly
mislabeled as: “bath salts not for human consumption”, “research chemicals” or “plant food” [75,
77, 116]. We investigated the effect of MEPH and MDPV together, as might be expected for bath
salts samples. Figure 12 shows currents in hDAT-expressing oocytes voltage clamped at -60 mV.
Different ratios of MEPH/MDPV were continuously perfused for the entire duration of the
experiment. From top to bottom the ratios of MEPH/MDPV (in µM) are 1/19, 5/15, and 15/5. In
mixtures composed predominantly of MEPH (lowest trace), we observed initial large size inward
current that eventually reversed as the comparatively lower concentration MDPV blocked hDAT.
In mixtures composed predominantly of MDPV (top trace), the effect is essentially a long-lasting
inhibitory current. The kinetics of MEPH are more rapid than the kinetics of MDPV in terms of
their ability to either elicit or block current through hDAT. We hypothesize that in vivo, assuming
equal concentrations of both compounds in the brain, there could be a reinforcement of DA for
bath salts abusers caused by: 1) exocytotic release due to MEPH-induced transient depolarization,
and 2) retention of DA in the synapse due to long-lasting MDPV block of hDAT.
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1 MEPH/ 19 MDPV

5 MEPH/ 15 MDPV
15 MEPH/ 5 MDPV

Figure 12: Bath salts currents hDAT currents induced by continuous exposure of different
proportions of bath salts components in hDAT expressing oocytes, V = -60 mV: MEPH/MDPV
(substrate/blocker) (in mM): 1/19, 5/15 and 15/5 (n = 3, grey color represent SEM).
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3.3. STP-induced persistent current at hDAT

3.3.1. IPC is dependent on intracellular STP concentation

In Figure 13A we see raw traces from hDAT expressing oocytes voltage clamped at -60
mV. External 10 µM S-AMPH perfusion induced an ISTP that returned to baseline after 30 s
application. However, longer exposures to S-AMPH caused a persistent current after drug
removal. The longer duration of S-AMPH application, the greater the amplitude of IPC suggesting
that internal accumulation of S-AMPH might be imparing normal hDAT function and not allowing
it to close; hence, we named S-AMPH action a ‘molecular stent’ within the transporter. IPC does
not only depend on the duration of STP application but also on its concentration (Figure 13B).
Exposure to 10 µM S-AMPH for 20 s did not produce IPC in Figure 13B, while 20 s. exposure of
30 µM S-AMPH induce a pronounced persistent current. This suggests again that IPC is due to SAMPH accumulation, and it acts at an intracellular site. To directly test our ‘internal action’
hypothesis, we titrated vaious concentrations and/or volumes of S-AMPH into hDAT expressing
oocytes voltage clamped to -60 mV. DA-induced hDAT current swiftly and consistently returned
to the original baseline prior to STP exposure (Figure 13C, left trace). Prior to injection of SAMPH inside of the oocyte, DA external application produced IDA; however, after injection of SAMPH a persistent current was observed after DA wash-out. We were able to affect the IPC
magnitude by either repeated injections of the same concentration or by using a single higher
concentration injection of S-AMPH, therefore confirming the involvement of internal S-AMPH in
the IPC phenomenon [2].
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Figure 13: IPC is time and concentration dependent and is induced by internal STP (Figure
adapted from [2]) A) S-AMPH (10 µM) induced inward peak current for exposures less than
30 s; however, for longer exposure times, a current that we term IPC remained long after SAMPH had been removed, and the amplitude of IPC was proportional to the exposure duration.
S-AMPH peak currents were normalized to the briefest exposure time. B) A relatively brief and
initial exposure to S-AMPH (20 s), which ordinarily would not produce a persistent current,
did so if the concentration of S-AMPH was increased from 10 to 30 µM. C) Dopamine, which
ordinarily would not produce IPC (left trace), induced a persistent current after 25 µM internal
injection of S-AMPH (middle trace). Doubling the internal S-AMPH concentration (second
injection) resulted in the generation of a larger IPC (right trace).
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3.3.2. IPC does not depend on the lipophylicity of STPs

Amphetamine is lipophilic and can partition through the membrane. It was suggested that
certain drugs produce long lasting depolarizing currents through hDAT due to accumulation of
these lipophilic compounds in the oocyte [119]. According to the lipophilicity model of IPC, when
drugs are washed away, passive diffusion and partitioning of accumulated drugs to the outside
will activate hDAT externally [119]. Figure 14 plots the magnitude of the persistent current
measured 60 seconds after removal of compounds (10 µM) against the lipophilicity repesented
represented using logP. logP if the octanol/water partition coefficient expressed in logarithm form.
Its values were obtained from chemicalize.org. High logP values represent more lipophilic
molecules that would more easily penetrate lipid membranes and reach molecular targets such as
ion channels, receptors, and in this case DAT. Figure 14 shows that S-AMPH and R-AMPH,
which have the same logP, differ in their ability to generate a persistent current: S-AMPH induced
IPC, while R-AMPH did not. Considering that both enantiomers of AMPH are equipotent in
inducing ISTP in hDAT-expressing oocytes (1.31 ±0.22 for R-AMPH and 1.25±0.14 for S-AMPH,
data not shown), lipophilicity cannot explain the differences observed in their ability to produce
IPC. In addition, S-AMPH and S-METH have different logP values, yet the two compounds have
approximately the same amplitude IPC. Finally, S-MCAT has the highest persistent current of the
group we studied, but is not the most lipophilic providing additional evidence that lipophilicity is
uncorrelated with the ability of STPs to produce a persistent current.
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Figure 14: IPC vs. lipophilicity. (Figure adapted from [5]). hDAT expressing oocytes, V= -60
mV, room temperature. All drugs are applied for 60 s and at 10 µM in concentration. The
persistent current is given as a fraction of the DA-induced current for each oocyte to normalize
for expression levels from cell to cell. The logP values were obtained from chemicalize.org.
Mean +/- SEM (n ≥ 5).
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3.3.3. IPC is induced by a unique conductance state of hDAT

In order to definitively state that IPC is caused by a unique conduction state of hDAT, we
compared the current-voltage relationships, I(V), of S-AMPH-induced ISTP and IPC in Figure 15.
All I(V) curves are buffer-subtracted to show only the drug-induced changes in conductance. The
I(V) for IDA has a negligible slope at more positive potentials, interpreted as a blockade of
endogenous conductance by DA [23]. Unlike DA, the S-AMPH-induced ISTP I(V) curve shifted to
the left and has a reversal potential of approximately 0 mV. The S-AMPH IPC I(V) was further
shifted to the left compared with STP and had a Vrev = -20 mV. This is the reported reversal
potential of Cl- in oocytes and is further in agreement with previous publications of Clinvolvement in substrate-induced currents [24, 25].
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S-AMPH, ISTP

IDA

S-AMPH, IPC

Figure 15: Current-voltage relationship of IDA, ISTP, and IPC (Figure adapted from [2]).
Baseline subtracted I(V) curves for DA, S-AMPH peak (ISTP) and S-AMPH persistent current
(IPC). The S-AMPH ISTP I(V) is shifted to the left above -60 mV compared with the DA peak
and reversed at 0 mV. The S-AMPH IPC I(V) is further shifted to the left and Vrev was at -20
mV suggesting the flow of Cl- ions.
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3.3.4. IPC causes a dysfunctional DAT state

As seen in Figure 13B, high concentrations of externally applied S-AMPH lead to more
pronounced IPC. In Figure 16, we applied 100 µM S-METH to produce a large persistent current.
Allowing some time for S-METH wash, substrates (10 µM DA and 100 µM S-METH) were pulsed
to interrogate the conduction state of DAT. Surprisingly, neither DA nor S-METH were able to
stimulate DAT currents from the IPC state, albeit the partial current recovery during the wash. It
appears that S-METH locks hDAT in a conformation that is unable to interact with its substrates
or induce currents upon external substrate application. To discriminate between transporter
dysfunctional and transporter internalization (research shows DAT down-regulation in response
to substrate exposure [120]), we designed a functional experiment to test transporter presence at
the membrane.
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Figure 16: S-METH induced dysfunctional hDAT hDAT expressing oocytes, V= -60 mV.
100 s application of 100 µM S-METH induces a large IPC. 30 s pulses of 10 µM DA at 2, 4, and
10 min after wash out cannot stimulate hDAT to elicit currents. 30 s pulse of 100 µM S-METH
at 5.5 min was also unable to stimulate the transporter to elicit currents.

54

3.3.5. DAT’s dysfunctional state can be reversed using reuptake inhibitor
In Figure 17 we took advantage of COC’s inhibitory action at hDAT to test if the
transporter was unresponsive to substrates due to an IPC-induced dysfunctional state, or due to
change in surface expression of hDAT. COC eliminated or reduced all hDAT-mediated currents
reflected in the upward deflection of current that levels off above the original baseline (Figures 4,
6, 9, and 10). In this experiment a 10 µM DA pre-pulse was followed by 100 s exposure to 60 µM
S-METH. A large IPC was induced upon wash out of S-METH. One minute following removal of
S-METH, 10 µM COC was perfused. As seen in Figure 17, COC was able to block both the IPC
and IL. This demonstrates that the unresponsiveness of hDAT is due to a conformational change
of the transporter upon interaction with internal S-METH, not due to its down-regulation.
Additionally, a DA stimulus was delivered following COC block and an inward current with
similar amplitude was observed, indicating that S-METH locks hDAT in a conduction mode not
responsive to external stimulus, possibly due to a new conformational state that cannot form
interactions with substrates that are necessary for eliciting substrate-induced currents. When DA
was removed, the current did not return to the original baseline but IPC was maintained, likely due
to internal S-METH accumulation. To test the effect of Na+ on IPC, the cell was perfused for 30 s
with Na+-free, NMDG containing Ringer buffer. NMDG induced a pronounced upward shift in
the current due to the inhibition of Na+ conduction through hDAT and possibly other oocyte
endogenous Na+ pathways, which are inward at -60 mV [2, 23]. When Na+ was reintroduced during
the subsequent DA application, IDA was generated and IPC ensued after the wash, likely due to the
presence of internal S-METH.
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Figure 17: COC recovers hDAT from substrate-insensitive state hDAT expressing oocytes,
V= -60 mV. 90 s. application of 60 µM S-METH induces large IPC. 10 µM COC eliminates
both IPC and IL. Following the block, 10 µM DA pulse is able to illicit IDA; nevertheless, IPC is
observed upon DA wash out. 10 µM COC blocks hDAT current. Second DA pulse elicits IDA
of the same magnitude as the 1st pulse. 30 s removal of Na+ (substitution with equimolar
NMDG) eliminates hDAT and oocyte endogenous conductances. Upon introduction of Na+ the
new baseline is still more depolarized compared to the original. Addition of 10 µM COC
reduces hDAT’s constitutive leak and removal of Na+ for 1 min now is able to eliminate
hDAT’s IPC. However, activation of hDAT with a 30 s DA pulse is able to again incur IPC.
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3.4. hDAT expression in mammalian cells

To investigate the implications of hDAT currents in more complex systems, we first
assayed DA and STP effects in FlphDAT cells; a stable inducible cell line. Immunostaining in
conjunction with confocal microscopy showed membrane localization of hDAT in FlphDAT cells
three days after doxycycline induction (Figure 18), whereas the parental Flp-In T-rex 293 cells
showed no hDAT expression (data not shown). In addition, hDAT protein levels were also
visualized using Western immunoblotting. As seen in Figure 18 right, hDAT was absent in parental
Flp-In cells and present in doxycycline induced FlphDAT cells. Equal amounts of protein loaded
were confirmed using antibody against GAPDH.
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Figure 18: Expression of hDAT in Flp-In T-Rex mammalian cells (left) Confocal image
shows hDAT expression in FlphDAT cells (red stain concentrated at the membrane). DAPI
nuclear staining appears in blue. (right) Parental Flp-In and FlphDAT were cultured and lysed to
confirm expression of hDAT using Western immunoblotting. Antibodies against human hDAT
and GAPDH were used as listed in “Methods”.
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3.4.1. hDAT currents in HEK 293 cells

In Figure 19 we compare the hDAT current elicited by DA and S-AMPH application under
voltage clamp at V= -60 mV and physiological temperature. The currents are obtained from hDAT
transiently transfected HEK 293 cells. 10 µM DA induces an inward current that returns to baseline
when DA is removed. 30 s of 10 µM S-AMPH induces a similar inward peak current; however,
the return of current upon wash out of S-AMPH is slower and persists tens of seconds for up to
one minute. DA and S-AMPH are overlaid for better comparison of kinetics. Using a monoexponential function, the time constants for the current decay were obtained: τDA= 1.3 s, τSAMPH= 5.1 s, τS-AMPH/τDA= 3.8 [5]. The results agree with a study conducted by Sandtner et
al.

comparing

serotonin

(5-HT),

p-chloroamphetamine

(pCA),

and

methylenedioxymethamphetamine (MDMA) responses in hSERT-expressing Xenopus laevis
oocytes and HEK 293 cells [119]. In oocytes, pCA-induced hSERT currents decayed 4 times more
slowly than 5-HT with a half-life of 20 s and 5 s, respectively. In HEK 293 cells, the pCA-induced
current decayed 5 times more slowly than 5-HT, 2.5 s vs. 0.5 s respectively. Thus for Sandtner et
al. the persistence ratio for drug to substrate was comparable in oocytes and HEK cells. Reviewing
the τ of both this study and Sandtner et. al. published results, we see: 1) the absolute value of the
off kinetics between oocytes and mammalian cells are 10 fold different with mammalian kinetics
being faster, and 2) the ratio of the off kinetics of psychostimulant to control (endogenous
substrate) is comparable in both expression system, approximately 4-5 fold difference.
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Figure 19: Persistent current in hDAT transfected HEK cells Current through hDAT
transiently transfected HEK 293 cells. V= -60 mV, T= 37°C. 30 s of 10 µM DA induces an
inward current that returns to baseline when DA is removed. 30 s of 10 µM S-AMPH induces
a similar inward peak current; however, the return of current upon wash-out of S-AMPH is
slower and persists tens of seconds for up to one minute. DA and S-AMPH are overlaid for
better comparison of kinetics. Using a mono-exponential function, the time constants for the
current decays were determined: τDA= 1.3 s, τS-AMPH= 5.1 s, τS-AMPH/τDA= 3.8. Figure
adapted from [5].

60

3.4.2. Potency of S- and R- AMPH differs in mammalian cells

In Figure 20 we explore hDAT currents in FlphDAT cells, voltage clamped to -60 mV using whole
cell voltage clamp technique. We compare the currents elicited by various concentrations of DA,
S-AMPH, and R-AMPH following a 30 µM DA pre-pulse. S-AMPH-induced inward currents with
higher potency than DA and R-AMPH. Dose response curves were fit to Hill equation using Origin
8:
𝑥𝑛
𝑦 = 𝑆𝑇𝐴𝑅𝑇 + (𝐸𝑁𝐷 − 𝑆𝑇𝐴𝑅𝑇) 𝑛
𝑘 + 𝑥𝑛
where x is the concentration of the tested compound, y is the response measured, START is min
response and END is the maximal response, k is the concentration that yield half–maximal
response, and n is the Hill slope parameter. EC50 = 1.50 ± 0.29 μM, 0.31 ± 0.04 μM, and 0.63 ±
0.27 μM for DA, S-AMPH, and R-AMPH respectively. The efficacy of DA and S-AMPH was
comparable (99 % and 101 %) while R-AMPH appears less efficacious similar to oocyte results
(85 %) [50, 121]. A 2.4-fold potency difference appears between S- and R-AMPH in mammalian
cells, which is not present in oocytes (equipotent in oocyte expression system). A 6.3-fold potency
difference exists between the S- and R-AMPH enantiomers, was reported by Sitte et al. in HEK
293 cells stably expressing hDAT [50]. Possible reasons behind the potency variation between
expressions systems and studies will be examined later in the Discussion.
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Figure 20: Dose-response curves for DA and AMPH enantiomers in mammalian cells
FlphDAT cells clamped at -60 mV were exposed to a constant DA pre-pulse and a variable pulse
of DA, S-AMPH, and R-AMPH. The full dose-response curves were fit to Hill1 equation and
yield the following fitting parameters: EC50 = 1.50 ± 0.29 μM, 0.31 ± 0.04 μM, and 0.63 ± 0.27
μM and Hill Slope = 1.6 ± 0.1, 0.93 ± 0.1, and 0.78 ± 0.2 for DA, S-AMPH, and R-AMPH
respectively. Each point shows mean ± SEM, n ≥ 5.

62

3.4.3. hDAT-induced currents are electrically coupled to voltage-gated Ca2+ channels
To study the possible electrical coupling of hDAT and voltage gated Ca2+ channels, the
voltage dependence of CaV1.2, CaV1.3, and CaV2.2 was determined in transiently transfected HEK
293T cells. Figure 21 shows the I(V) relationship of the Ca2+ currents measured under whole-cell
voltage clamp. The voltage dependence of the currents was fit to the following equation:
ICa (V ) 

Gmax (V  Vr )
V  V 
1 exp 1/ 2

 k 

where Gmax is the maximal conductance, V is the test potential, V1/2 is the potential at which G=1/2


Gmax, k represent a slope parameter, and Vr is the reversal potential.
Using this equation the test potential that yielded half of the maximal conductance (V1/2)
was –25.6 ± 1.0 mV (n=8), –3.2 ± 0.8 mV (n=7) and +5.5 ± 1.0 mV (n=8) for CaV1.3, CaV1.2 and
CaV2.2, respectively. The 30 mV range of V1/2 the three channels under investigation illustrates
the variability in high-voltage activated CaVs. It is easy to imagine that depending on the
expression levels of specific type CaV, similar amounts of depolarization may have or not an effect
on excitability and neurotransmitter release.
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Figure 21: Voltage dependence of Cav1.3, Cav1.2, and Cav2.2 Voltage dependence of
CaV1.2, CaV1.3 and CaV2.2- mediated Ca2+ currents: HEK 293T cells were co-transfected with
β3, α2δ, and EGFP expression plasmids plus alternatively CaV1.3, CaV1.2 or CaV2.2 plasmids.
Recordings were carried out at room temperature under constant perfusion. Test pulses in 5 mV
steps for CaV2.2 or 10 mV steps for CaV1.2 and CaV1.3 were applied from a holding potential
of -80 mV. Representative responses are shown for CaV1.3 (light grey circle), CaV1.2 (dark
grey triangle) and CaV2.2 (black square) and the magnitude of the test potentials are indicated
in mV. V1/2 = -25.6 ± 1.0, -3.2 ± 0.8 and 5.5 ± 1.0 mV, CaV1.3 (n=8), CaV1.2 (n=7) and CaV2.2
(n=8), respectively. Figure adapted from Cameron, Solis, Ruchala, De Felice, and Eltit,
submitted for publication.
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To determine if depolarization by S-AMPH- or DA-induced hDAT currents is sufficient to
activate voltage-gated Ca2+ channels, Ca2+ signals were measured using the Ca2+ sensitive dye
Fura-2AM in FlphDAT cells transfected with CaV1.2, CaV1.3, or CaV2.2 (Figure 22). Both, 5 s
application at 35 °C of saturating concentrations of 10 μM DA (upper panel) or 5 μM S-AMPH
(lower panel), produced Ca2+ signals in FlphDAT cells expressing CaV1.3 or CaV1.2. The S-AMPH
and DA stimulated increase in Ca2+ signal was blocked by 2 μM isradipine, a potent L-type Ca2+
channel blocker. Conversely, under the same conditions, the intracellular Ca2+ concentration did
not change in FlphDAT cells expressing CaV2.2 (right trace). As seen in Figure 21 CaV2.2 requires
the highest amount of depolarization to activate: + 5 mV. Depolarization induced by a sequential
exposure to high K+ external solution (right trace, top and bottom) yielded a convincing Ca2+
transient demonstrating adequate expression of CaV2.2 in the cells, hence, insufficient hDATinduced depolarization to activate this type of channels.

65

Figure 22. S-AMPH- and DA-induced hDAT currents activate CaV1.2 and CaV1.3, but
not CaV2.2. Intracellular Ca2+ determinations in Fura-2AM loaded Flp-hDAT cells evaluated
by fluorescence microcopy, under constant perfusion and at 35°C. Flp-hDAT cells were cotransfected with CaV1.3, CaV1.2 or CaV2.2 plus β3, α2δ and EGFP plasmids. Transfected cells
were identified by their EGFP signal and then briefly exposed to 10 µM DA, 5µM S-AMPH,
or 130 mM K+ as indicated in the timeline of each panel. 2 μM isradipine eliminates Ca2+ signals
induced by both hDAT substrates. Each trace shows the mean ± SEM, n ≥ 81. Figure adapted
from Cameron, Solis, Ruchala, De Felice, and Eltit, submitted for publication.
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In Figure 22 we saw that both DA and S-AMPH application can activate CaV1.3 and
CaV1.2. To rule out a direct activation of CaV channels by DA or S-AMPH, intracellular Ca2+ was
determined in the presence of a potent hDAT blocker, MDPV [1, 6]. This reuptake inhibitor, as
described earlier, blocks current and uptake with extremely high potency. Figure 23 shows
perfusion of 1 µM MDPV eliminates both DA and S-AMPH-induced Ca2+ transients in FlphDAT
cells expressing either CaV1.2 or CaV1.3. A control showing that MDPV does not directly interact
with CaVs, hDAT-independent depolarization was induced by high K+ produced Ca2+ signals
refractory to MDPV treatment.
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Figure 23: hDAT blockade prevents L-type Ca2+ channel activation in FlphDAT cells
Intracellular Ca2+ concentration was determined by fluorescence microscopy in Flp-hDAT cells
co-transfected with CaV1.3 or CaV1.2 plus β3, α2δ and EGFP plasmids, using the Ca2+ sensitive
dye Fura-2AM. The experiments were carried out under constant perfusion at 35°C. The
transfected cells were identified by their EGFP signal and then were briefly exposed to 10μM
DA, 5μM S-AMPH or 130 mM K+ as indicated in each panel. hDAT blocker MDPV (1μM)
prevented Ca2+ signals induced by substrate-induced hDAT currents. Each trace shows the
mean ± SEM, n ≥ 60. Figure adapted from Cameron, Solis, Ruchala, De Felice, and Eltit,
submitted for publication.
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The depolarization induced by DA- or S-AMPH- hDAT interactions activates both L-type
CaVs: CaV1.2 and CaV1.3. Dose –response effects measuring Ca2+ signals and hDAT current
elicited by DA and S-AMPH in FlphDAT are shown in Figure 24. S-AMPH appears more potent in
activating the two L-type Ca2+ channels (top panel) with EC50 of 144 ± 11 nM and 102 ±16 nM for
CaV1.2 and CaV1.3 respectively, while the less potent DA has EC50 values of 916 ± 54 nM and 693
± 25 nM, respectively.
To better understand the electrical coupling between hDAT and the L-type Ca2+ channels,
dose-response curves for DA- and S-AMPH-induced hDAT currents were generated (Figure 24,
bottom left). Although the EC50 values were 5-fold different, 1.44 ± 0.24 μM and 0.28 ± 0.04 μM
for DA and S-AMPH respectively, the efficacy were not different under the experimental
conditions used.
Lastly to see the coupling of hDAT currents and CaVs activation, we plotted Ca2+ signals
fits vs. hDAT current fits (Figure 24, bottom right). These curves show that S-AMPH, compared
to DA, generates a relatively larger Ca2+ transient in response to smaller hDAT inward currents.
With both DA and S-AMPH, CaV1.3 activated more than CaV1.2, confirming that it requires less
hDAT-induced depolarization to open. From this plot we see that small amplitude S-AMPHinduced hDAT currents were coupled tighter than DA to both CaVs activation.
.
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Figure 24: S-AMPH is more potent in producing Ca2+ signals, hDAT currents, and hDATCaV coupling Intracellular Ca2+ concentration was determined by fluorescence microscopy in
Flp-hDAT cells co-transfected with CaV1.3 or CaV1.2 plus β3, α2δ and EGFP plasmids, using
the Ca2+ sensitive dye Fura-2AM. (top) Dose-response curves were generated for DA and SAMPH activation of CaV1.2 or CaV1.3 through hDAT-induced depolarization. EC50 values in
CaV1.2: 916 ± 54 nM and 144 ± 11 nM for DA and S-AMPH respectively. EC50 values in
CaV1.3: 693 ± 25 nM and 102 ±16 nM for DA and S-AMPH respectively. (bottom left) hDAT
currents were measured using whole-cell voltage clamp, V= -60 mV, T= 35ºC. EC50 = 1.44 ±
0.24 μM and 0.28 ± 0.04 μM for DA and S-AMPH respectively. (bottom right) The Ca2+ signal
fits of both CaV1.2 and CaV1.3 are plotted against the normalized current fit to represent hDATCaV coupling. Figure adapted from Cameron, Solis, Ruchala, De Felice, and Eltit, submitted
for publication.
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3.5. hDAT current effect in neurons

3.5.1. LUHMES selection

To investigate the importance of hDAT currents on cellular excitability we chose a human
mesencephalic neuronal cell line, LUHMES. The line is subcloned of a source material derived
from eight-week-old human ventral mesencephalic tissue [122]. The committed neural precursor
cells were transformed with myc oncogenes for continuous proliferation [123]. Addition of low
tetracycline concentration abolishes the v-myc expression. DA phenotype is confirmed in many
studies [114, 122, 124]. In addition, the use of dbcAMP during differentiation, leads to TH
production; therefore, LUHMES synthesize and release DA [123]. To determine the optimal
conditions for our study with the highest expression of both dopaminergic and neuronal marker
we explored different time courses of differentiation. As seen in Figure 25, the cells undergo
dramatic morphological changes upon differentiation induction. Using inverted microscopy with
10x magnification we see undifferentiated cells at day 0 (left panel) have relatively large somas
and cell neurites are absent. Using 20x magnification, 5 days post differentiation the cells appear
to have short neurite network and the somas appear smaller and more round. At 10 days post
differentiation (20x magnification) the cells have long, dense network of projections and a small,
round cell body.
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Figure 25: Conversion of LUHMES from proliferating to post-mitotic neurons LUHMES
were differentiated for 10 days in presence of tetracycline, GDNF, and dbcAMP. Images of
undifferentiated (Day 0) and differentiated (Day 5 and 10) cells are shown. Cells undergo
morphological changes and appear as mature neurons at Day 10 with dense network of
projections and smaller and rounded cell bodies. Cells were examined using inverted
microscope using 20x magnification for day 0 and 40x magnification for days 5 and 10.
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3.5.2. Differentiation changes

Immunostaining in conjunction with confocal microscopy showed modest expression of
hDAT at 7 and 10 days of differentiation respectively. Figure 26, left panel, shows membrane
localized hDAT (red stain) at cell body and processes 10 days post differentiation. Staining for all
voltage-gated Na+ channels (NaVs, green stain- Pan antibody with epitope present in all NaVs in
vertebrates) appears at cell body and processes and partial co-localization with hDAT is observed
(not shown). DAPI nuclear staining appears in blue.
In attempt to boost hDAT’s expression level, the use of retroviral transduction of hDAT in
the parental LUHMES cell line was employed. To evaluate the expression level of hDAT in
parental and transduced LUHMES (LUHMEShDAT), we used Western immunoblotting of
undifferentiated and Day 7 of differentiation cells (Figure 26, right). Day 0 parental LUHMES
have no detectable levels of hDAT, while the transduced LUHMEShDAT show hDAT expression.
After 7 days of differentiation, parental LUHMES show a significant level of hDAT expression
(larger than transduced at Day 0), whereas LUHMEShDAT shows complete lack of hDAT. The
control GAPDH shows equal amount of protein is loaded for the comparison. Optimum hDAT
condition appears to be 7 days of differentiation of parental LUHMES.
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Figure 26: hDAT expression in Lund derived human mesencephalic cells (LUHMES)
(left) Confocal image shows hDAT (red stain) expression in LUHMES cells at 10 days of
differentiation. DAPI nuclear staining appears in blue. (right) LUHMES and hDAT transduced
LUHMES (LUHMEShDAT) were cultured and lysed before or 7 days post differentiation to
assay the expression of hDAT using Western immunoblotting. Antibodies against human
hDAT and GAPDH were used as listed in “Methods”.
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In order to better characterize the differentiation, in Figure 27 we analyzed the parental
LUHMES (top) and LUHMEShDAT (bottom) for seven genes of importance for neural and
dopaminergic phenotype using qPCR (quantitative polymerase chain reaction). To find the peak
for dopaminergic markers we chose to monitor mRNA levels for DAT, tyrosine hydroxylase (TH),
and dopamine receptor 2 (D2R). In addition, we were interested in finding the peak electrical
activity time point since we investigate activation of voltage-gated channels related to AP
generation; therefore, we chose to monitor endogenous dopaminergic channels: CaV1.3, CaV1.2,
NaV1.2, and G-protein-regulated inward-rectifier potassium channel 2 (GIRK2). Results were
normalized to the expression of GAPDH mRNA (control gene encoding glyceraldehyde phosphate
dehydrogenase) and are presented as fold difference relative to expression in undifferentiated
parental LUHMES (day 0).
Parental LUHMES displays an increase in mRNA levels of all genes in day 5 as compared
to day 0 with TH and CaV1.3 being absent at day 0 but in detectable amounts at day 5. The mRNA
levels of hDAT, both CaVs, and NaV continued to increase, revealed in day 10. For D2R, GIRK2,
and TH, the mRNA levels were lower at day 10 compared to day 5.
LUHMEShDAT appears in some ways similar to parental LUHMES: mRNA for TH and
CaV1.3 were undetectable at day 0 but present at day 5. All other genes of interested, except for
hDAT, were detectable at day 0 in equal amounts to the parental line. All genes of interst showed
increasing mRNA levels at day 5. hDAT appeared strongly upregulated at day 0 of transduced
LUHMES, 755-fold increase compared to parental line, and as expected it increased at day 5. The
levels of hDAT mRNA in LUHMEShDAT at day 5 were much higher than parental line (1538-fold
vs. 28-fold); however, this was the peak level observed in LUHMEShDAT and the peak in parental
line at 10 days was higher (1960-fold vs. 1538-fold). At day 10, the transduced line only showed
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increase in mRNA levels of CaV1.2 and NaV1.2. All other genes appeared to have decreasing
amount of mRNA, especially out target hDAT and TH was not detectable. As a result of the
findings we picked LUHMES differentiation of 7-9 days for further studies.
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Figure 27: Quantitative PCR analysis of dopaminergic and neuronal mRNA in LUHMES
and LUHMEShDAT Data from day 0, 5, and 10 of differentiation. Results are normalized to the
expression of GAPDH mRNA (control gene encoding glyceraldehyde phosphate
dehydrogenase) and are presented as fold difference relative to expression in undifferentiated
LUHMES (day 0). (top) Both neuronal and dopaminergic markers increase with days of
differentiation. CaV1.3 and TH are not detected before differentiation therefore data is
normalized to Day 5. (bottom) LUHMEShDAT values show initial high mRNA levels of hDAT
at day 0 which decline at day 10. CaV1.3 and TH are not detected before differentiation.
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3.5.3. STP effect on LUHMES excitability
LUHMES cells were differentiated for 9 days. Intracellular Ca2+ concentration was
determined by fluorescence microscopy using the Ca2+ sensitive dye Fura-2AM. The experiments
were carried out under constant perfusion at 35 °C. A 5 min perfusion protocol was designed to
monitor the change in excitability (transient Ca2+ increase in the cell soma due to CaV opening, no
increase from cellular stores).
While exploring for best imaging conditions, we discovered that the UV light used for
signal acquisition affects profoundly the cells. As a result, all measurements were acquired under
11% light intensity and 200x gain. Two recordings per set of cells were done. First, pictures were
taken under physiological imaging solution (IS-control set). The same set of cells is then exposed
to the test condition. During the course of investigation, we observed vastly different results in
cellular activity between different wells seeded with same number of cells. While some cells had
very little activity in both imaging solution and test condition, others appear to be dramatically
stimulated with the test condition. Upon further control testing (consecutive IS applications) we
determined that certain cells increase their activity yet again due to UV light used for signal
acquisition.
To eliminate the variability induced by the prolonged light exposure (2x 5 min), we used
only one 5 min Ca2+ measurement per set of cells. In Figure 28, three test conditions were used:
buffer solution showing background activity, 2 μM S-METH, and 2 μM S-METH in Ca2+ free
buffer. Due to difficulty of identifying and selecting active projections from single cell (very dense
and complex network) data were only collected from the cell somas. All cells within the imaging
frame were selected and data were exported and manually reviewed for Ca2+ increases indicative
of cell excitability. To compare between control (IS) and test conditions (2 μM S-METH and 2
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μM S-METH in Ca2+ free buffer), % excitable cells was calculated for each frame which equates
# cells with Ca2+ signal increase above 0.5 / total # of cells in that frame * 100. As many as 11
frames were acquired and used for the calculation of the final mean. The results are expressed as
mean ± SEM. In comparing control buffer (IS) condition to S-METH we saw an increase in cell
excitability; however, the difference was not statistically different. Due to the high variability
between cells, additional recordings could be beneficial in decreasing the error and possibly
turning the increasing trend to being statistically different.
The second test condition tested was S-METH application in Ca2+ free buffer. This
experimental condition was used to determine if the Ca2+ increase comes from outside source
through the activation of CaVs similar to our finding in Figures 22 and 23, or from internal store
release. The % excitable cells decreased significantly (p < 0.05) in Ca2+ free conditions.
In the course of the study using LUHMES it was established that this cell line shows low
spontaneous activity and due to the requirement for highly confluent cells, voltage clamp and
current-clamp experiments were not within our reach. This cell line would be best for performing
biochemical analyses which require a large number of cells.
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Figure 28: Excitability of LUHMES LUHMES cells were differentiated for 9 days.
Intracellular Ca2+ concentration was determined by fluorescence microscopy using the Ca2+
sensitive dye Fura-2AM. The experiments were carried out under constant perfusion at 35°C.
The cells were exposed to 2 μM S-METH or 2 μM S-METH in Ca2+ free buffer. The % of
excitable cells was calculated as # cells with increased intracellular Ca2+ above 0.5 / total # cells
*100. Each bar represent mean ± SEM, n ≥ 200.
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Chapter 4 DISCUSSION

In this work, we present novel results for the action of S-enantiomers of STPs on hDAT,
in particular, the effect of STPs on transporter currents that modulate voltage-gated channels
involved in dopaminergic excitability. DAT currents are much larger than the predictions of fixed
stoichiometry transport: 1DA, 2 Na+, and 1 Cl- which would produce only 0.16 pA current if 1
million transporters would be active simultaneously. Relatively large DAT currents are measured
not only in over-expression systems but also in dopaminergic neurons [1, 2, 6, 25, 47, 125]. The
role of DAT currents is not clear at this time; however, because the current is relatively small in
amplitude and it can persist after stimulation is removed, we hypothesize that it would have an
influence on neuronal excitability.
Our results suggest when an STP is transported into the cell through hDAT, it accumulates
inside the cell and interacts with an internal site on hDAT, since a persistent current is observed
after STP removal. This interaction interferes with transporter’s swift closure upon STP removal
resulting in a long-lasting depolarization after external STP exhaustion (longer than would persist
with DA). The presence of a persistent depolarization in a neuron may have an effect on neuronal
excitability, a probability of neurotransmitter release, and could potentially be toxic. Furthermore,
we showed that once S-AMPH or S-METH accumulates inside the cell, hDAT has an altered
response towards its endogenous substrate, DA (DA stimulation now produces IPC), and in the
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Xenopus oocyte expression system, S-METH induces a dysfunctional state of the transporter that
does not respond to subsequent substrate exposure (i.e., does not elicit additional currents). This
dysfunctional state was reversed by COC, a DAT reuptake inhibitor. A subsequent DA pulse elicits
IPC after wash out since S-METH has built up in concentration inside of the oocyte. This
experiment in addition to the internal S-AMPH injections illustrates the long term effects that IPC
exerts on DAT function.
We found that in oocytes the persistent current is pronounced, with a clear shift in baseline
in addition to slowing the off-kinetics. When we performed equivalent experiment in mammalian
HEK 293 cells we saw a prominent difference in DA and S-AMPH off-kinetics; however, the
current does not establish a new baseline which is the case in oocytes. Although there are dissimilar
effects in the STP-induced DAT currents in the two expression systems, the ratio of STP/DA time
off is ~4. I.e., although HEK cells have faster kinetics than oocytes, this is true for DA as well as
for the STPs resulting in the same ratio. In both expression systems, the ratio of STP/DA time off
is ~4. Similar results are reported in SERT expressed in both oocytes and HEK 293 cells upon
exposure to pCA and 5-HT [119]. The off ratio of pCA/ 5-HT was determined to be ~ 4-5 [5, 119].
In addition to a no baseline shift in HEK 293 cells, we saw no effect of STPs on DAT
activity, in contrast to the effect observed in oocytes (data not shown). No matter the concentration
of the STP delivered (inside the cell through the patch pipette, or outside through perfusion) the
IPC remained unaltered or produced relatively minor shifts in the off-kinetics. A possible
explanation for the variable observations between oocyte and HEK 293 cell recordings could be
the difference in techniques employed. In TEVC used for the oocyte recordings, the inside of the
cell is not dialyzed which is the case in whole-cell patch-clamp employed with HEK cell
measurements. If there is a requirement for an important soluble component to observe IPC,
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perforated patch clamp techniques should eliminate the inconsistencies. Additionally, differences
in lipid composition, temperature of solutions (room T vs. 35 ºC), and secondary protein
interactions could account for the discrepancies.
A further suggestion that secondary factors exist that affect hDAT function in the two
expression systems is the finding that S- and R-AMPH, that appear equipotent in oocytes have a
2-fold potency difference in mammalian cells [2, 121]. Even more striking is the difference in
potency of the enantiomers to elicit hDAT currents under whole-cell patch clamp at physiological
temperature, with the only difference in the results coming from stable vs. transient transfection of
hDAT (data from Figure 21 and reference# [50]). Here we show 2-fold difference in EC50 values
of S-AMPH and R-AMPH, while Sitte et. al. report ~7-fold difference [50].
How do we explain the persistent current? Since we observe IPC after washout of the STP,
an internal site of STP action at the transporter is hypothesized. IPC is STP concentration- and timedependent supporting the hypothesis that STPs act at an internal site on DAT. Direct injection of
a STP inside the cell does not elicit any current; however, when an external stimulus is applied to
activate hDAT currents, IPC is observed. This finding suggests that the internal interaction must be
in a place that is not accessible in the closed state of hDAT; rather a specific conformation
(conducting state) is required for the STP to access a site and establish interactions that then
interferes with the swift closure of the transporter. One possible site for this interaction would be
near the internal transporter gate. A potential interaction at this location with residues forming the
gate or residues interacting with the gate would affect the proper closure of the transporter. Further
studies including molecular simulations and mutagenesis are warranted to answer this question.
Knowing the electrophysiological signature of the enantiomers of AMPH, we proceeded
to investigate the mechanism of action of components of bath salts. Bath salts consist of
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heterogeneous mixtures of various psychoactive substances, primarily synthetic cathinones. Drug
sample analyses reveal that bath salts can contain a complex mixture of compounds such as
cathinones (MEPH, MDPV, methylone, butylone, ﬂephedrone, etc.), other abused substances
(AMPH, MDMA, COC), and caffeine [75, 89]. Due to the wide range of compounds and
compound combinations found in bath salts it is important to identify their mechanisms of action
alone and in combination. Since MEPH and MDPV appear to be most prevalent on the market, we
explored those two compounds in greatest detail, individually and together in varying proportions
[1].
Our findings show that similar to AMPH and METH, MEPH is an hDAT substrate because
it produces an inward current at physiological membrane potentials under voltage clamp. Its
maximal current amplitude or efficacy is approximately 50% of IDA; however, MEPH induces a
large persistent current that is approximately twice in absolute value size of S-AMPH and SMETH-induced IPC under the same conditions, which would enhance its DA releasing capacity in
neurons [1, 6]. MEPH-induced IPC is 2nd largest after S-MCAT which may change if only the more
potent enantiomer is used. Other studies in synaptosomes report that MEPH inhibits dopamine
uptake in agreement with our findings that it has dopaminergic effects similar to the STPs [126].
This agrees with numerous other studies, presenting that both in vitro and in vivo MEPH appears
as a mixed, nonselective releaser of not only DA but also of 5-HT [3, 78]; hence, it resembles the
action of MDMA. Although MEPH is self-administered, in vivo studies on motor stimulation show
a modest increase, much lower compared to METH, pointing again toward dual dopaminergic and
serotonergic action [82].
3,4-methylenedioxypyrovalerone (MDPV) is a common bath salts component that we
discovered is not a substrate for hDAT [1, 6, 78, 127]. MDPV behaves similar to a cocaine-like
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dopamine reuptake inhibitor. Like COC, MDPV produces an outward current at hDAT and can
inhibit both ISTP and IPC when applied in succession to STP. Simmler et al. showed that MDPV has
a very high affinity for DAT [78]. MDPV is 20-30-fold more potent than COC in DAT transport
inhibition [1, 78]. In our electrophysiological assays, MDPV produced more outward hDAT
current than COC in oocytes voltage-clamped to -60 mV. This is a strong indication that COC
inhibits only partially hDAT’s endogenous leak current while MDPV inhibits more, or potentially
all, leak current. Under voltage clamp, MDPV produced a long-lasting outward current deflection,
while COC blockade of the endogenous DAT current was short-lived under the same conditions.
An in vivo rat ICSS study showed similarly a long-lasting effect of MDPV (Figure 29) [1, 3].
Bonano et. al show that MDPV produced ICSS facilitation that was significant after 300 min
(upward triangle, Figure 29), with facilitation still present 24 h after drug administration [3]. The
recovery of hDAT current following MDPV inhibition was investigated first in oocytes and
compared to DAT current recovery following COC block. There was 100% recovery of DAinduced hDAT current 1 min after COC blockade, whereas 1 min after MDPV block there was
11% recovery IDA and 30 min later there was only 45% recovery which we hypothesize may be
partially due to hDAT up-regulation induced by reuptake inhibitors.
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Figure 29: Time courses (±)-MDPV effects on full ICSS frequency– rate curves. Drug
effect of 3.2 mg/kg (±)-MDPV. Abscissae: frequency of electrical brain stimulation in log Hz.
Ordinates: percent maximum control reinforcement rate (%MCR). Filled points represent
frequencies at which reinforcement rates were statistically different from vehicle rates as
determined by two-way ANOVA followed by Holm– Sidak post hoc test, p<0.05. All data
show mean ± SEM for six rats. Figure adapted from [3].
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To test if MDPV has also a long-lasting inhibitory effect on hDAT uptake, its action was
tested in HEK 293 cells under no voltage clamp. In this case we tested not the ability of hDAT to
elicit DA currents, but rather the transport process itself. We took advantage of an hDAT
fluorescent substrate (APP+ [111]) and showed that after MDPV block, it took 5 min for the
transporters to completely recover their rate of transport as compared to immediate recovery after
COC block. We may speculate that either MDPV is still present and available after external
removal (e.g. due to high lipophilicity [78]), or MDPV induces a long-lived conformational state
in hDAT.
An interesting finding about IPC was revealed while testing the COC and MDPV block of
hDAT currents. When COC and MDPV were applied to baseline current levels (before DA or STP
exposure), both compounds elicited long lasting inhibitory effects (reflected in a stable outward
current deflection for minutes). However, when COC and MDPV were applied during a persistent
current state of the transporter, the outward current (above baseline level) was long-lasting only in
the case of MDPV whereas COC’s block reversed to IPC as soon as the compound was washed out.
These findings suggest that the IPC is a distinct conduction state of the transporter rather than an
exaggerated IL.
It is known that both MEPH and MDPV enhance DA neurotransmission [3]. Whereas bath
salts are not well deﬁned as a mixture, samples include MEPH, MDPV, methylone and other
compounds [83]. So far, most studies report exposure to single cathinone analogue; therefore we
explored how two synthetic cathinones act together when applied simultaneously to hDAT. We
observed a two-component response separated by a few seconds: first, an inward current induced
by the substrate MEPH ensued followed by the outward current induced by MDPV [1]. The
magnitude and duration of the inward current depended on the concentration balance of the two

87

compounds. These results suggest DA release could precede DA uptake blockade in a mixture of
bath salts containing MEPH and MDPV. Furthermore, the blockade of hDAT by MDPV is longer
lasting than the blockade by COC, hence, a long-lasting neurochemical, physiological, and
behavioral effects would be observed [3]. Although in vitro experiments are far removed from the
in vivo conditions of drug abuse, this synergistic combination may be especially dangerous to the
user for whom the combined action of releasing drugs and blocking drugs is greater than the sum
of their individual effects.
Studies in dopaminergic neurons report increased excitability (firing rate) caused by
substrate-induced DAT currents [24, 25, 59, 125]. The reports show that DAT-dependent increases
in neuronal excitability display results during drug application (i.e., ISTP and IDA). Moreover, some
reports highlight that only low concentrations of STPs enhance neuron firing and
neurotransmission, whereas high concentrations of substrate inhibit firing as a result of D2
autoreceptor activation [125]. In our studies we explored possible cross-talk of hDAT and specific
L- (CaV1.2 and CaV1.3) and N-type (CaV2.2) CaVs co-expressed in mammalian Flp-In T-rex 293
cells. These voltage-gated Ca2+ channels are, reportedly, involved in dopaminergic neuron
excitability (L-type) and vesicular fusion (N-type). Our results demonstrate that DA- and SAMPH-induced hDAT currents are sufficient to depolarize the cells enough to activate both Ltype Ca2+ channels (CaV1.2 and CaV1.3) but not N-type (CaV2.2). This is not a surprising finding
as a broad range of voltage sensitivity is observed among Ca2+ channels. CaV1.2 and CaV2.2 have
a ~20 mV and ~30 mV right shifted voltage dependence compared to CaV1.3 respectively. These
results indicate that the hDAT-mediated depolarization is in the range of the activation threshold
of some CaVs: L-type (CaV1.2 and CaV1.3) but not N-type (CaV2.2) CaVs are within the activation
range of hDAT-mediated depolarization under our experimental conditions. The results also
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suggest that S-AMPH- and DA-induced currents through hDAT are qualitatively different, with
S-AMPH producing greater L-type channel activation. One explanation for the difference could
be the different ionic composition of IDA and ISTP as reported by Rodriguez-Menchaca et. al.
(different reversal potentials with DA and S-AMPH I(V)s crossing at – 80 mV) [2]. Another
possible explanation for the S-AMPH superiority in activating CaVs at low transporter steady-state
current levels is the existence of transient peak current that can be resolved under piezoelectric
rapid solution exchange [47]. This transient peak current which is several folds larger than the ISTP
decays rapidly to form the steady state peak current which we name ISTP. Although ISTP it is also
present with DA, it is reported to be significantly larger in AMPH [47].
To understand better the coupling of IDA or ISTP to Ca2+ channel activation, we looked at
the Ca2+ signal to hDAT current relationships of DA and S-AMPH at CaV1.2 and CaV1.3. The
results were consistent with the voltage-dependence of the channels: CaV1.3 which displays the
lowest voltage dependence had greater coupling strength for S-AMPH and DA as compared to
CaV1.2. The initial high coupling strength values at low IDA and ISTP may activate a small
percentage of the lowest threshold CaV1.3 whose Ca2+ conductance may favor further
depolarization which would recruit more CaV1.3 thus potentiating the coupling-strength. At higher
IDA and ISTP, increase in internal Ca2+ may induce channel saturation and inactivation, thus
decreasing the coupling-strength. Furthermore, in dopaminergic neurons the increase in
intracellular Ca2+ causes Ca2+ activated K channels to open and re-polarize the cells.
In this study we show that hDAT is electrically coupled to L type CaVs important in cell
excitability. We have also presented that in addition to the peak current, STPs generate a persistent
current (IPC) through hDAT. We hypothesize that IPC would prolong depolarization induced by
STP after washout and although in the synapse the voltage is not clamped but rather dynamic, the
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effect of the internal STP could be elicited after either tonic or phasic DA release upon uptake.
Moreover, cell depolarization is shown to impair DA uptake [10, 11, 128], therefore, IPC may
contribute through several different mechanisms to extracellular DA augmentation associated with
drug addiction. Interestingly and in addition to the increased excitability due to hDAT
conductance, at high STP concentrations several reports show that instead of enhancement of
dopamine neurotransmission and dopamine neuron firing, the opposite is observed [24, 125].
Autoinhibitory D2 receptors are activated by the released DA and neuronal firing is decreased
[125]. The caveat again is that under hyperpolarized conditions, DAT exhibit a more efficient
uptake, so more STP or DA would enter the cell and as I(V)s show, at hyperpolarizing potentials
IDA and ISTP are larger [2, 10, 11, 128]. Hence, we designed experiments to test our hypothesis on
increased neuronal excitability due to hDAT currents: ISTP and IPC. For this purpose we selected a
neuronal cell line from human mesencephalon, LUHMES, which has been immortalized for
continuous proliferation and continuous formation of committed dopaminergic neuronal precursor
cells. Upon completion of biochemical analyses to determine the best conditions for expression of
both dopaminergic and neuronal markers, we identified a few potential problems that affected our
future work. The cells have a low hDAT expression. After 7 days of differentiation we did not
detect hDAT-specific uptake using the fluorescent substrate APP+ (data not shown). Furthermore,
only approximately 10 % of cells appeared spontaneously active, and even transduction with
hDAT aimed at increasing hDAT’s levels was unsuccessful in producing larger effects, apparently
due to early down-regulation or degradation of transporters during the differentiation process. In
addition to these challenges, the cells undergo dramatic morphological changes during
differentiation, grow long and dense network of projections while the soma becomes small and
round making it technically difficult to voltage-clamp or current-clamp the cells. To overcome

90

those obstacles, we took a different approach to monitor the cellular excitability: we measured
Ca2+ signals as we did with FlphDAT. The Ca2+ dye acts almost as a voltage sensor since we show
that CaVs activation require certain amount of depolarization. In addition, we can confirm that
increases in internal Ca2+ are due to voltage-gated channel activation rather than release from
internal stores since we can easily manipulate extracellular Ca2+ as in out experiment. We faced
further hurdles with the Fura-2 Ca2+ signals measurements due to UV light-stimulated LUHMES
activity. Although we decreased the UV light to only 11% intensity, we could still see increase in
Ca2+ signals with some cells during our 10 min experimental protocol (5 min buffer/control, 5 min
test condition). Finally we acquired 5 min signal for single condition and increased the number of
measurements to get a reliable mean value. The results from our study suggest that additional
image acquisitions will be necessary. Nevertheless, an increasing trend in excitability occurred by
this measure between control/buffer and S-METH application; however, due to the large statistical
error we saw no significant difference in the values. On the other hand, there was a significant
decrease in excitability when the external Ca2+ was removed, confirming the importance of CaVs
in dopaminergic neuronal excitability [94, 101].
In summary, this investigation on the conduction states of the dopamine transporter reveals:
1) reuptake inhibitors could exert only partial block of hDAT’s endogenous leak current as seen
with COC and MDPV, 2) substrate type psychostimulants (STPs) induce a steady-state peak (ISTP)
and a persistent current (IPC) through hDAT, 3) DA and STP induced currents (IDA and ISTP) may
activate L-type voltage-gated Ca2+ channels, 4) L-type CaVs activation increases dopaminergic
excitability and removal of external Ca2+ abolishes neuronal firing. Additional studies are required
to investigate the possible effects of IPC on neuronal excitability and DA release, i.e. compare the
excitability induced by S- and R- enantiomers of STPs. As discussed earlier, depolarization by the
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STPs would cause exocytotic DA release, and the uptake of DA would be interfered by not only
STP competition for transport but also by depolarization-induced DAT uptake slowing down, and
D2 receptors hyperpolarization. That however, would cause DAT uptake to become more efficient
and STPs would once again elicit larger currents. Understanding this complex mechanism of action
of drugs at hDAT is of great importance since a number of synthetic cathinones have invaded the
clandestine market and we have shown that some act through DAT and produce large persistent
currents with physiological effects after their removal [1, 6].
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